2024-03-28T11:24:27Z
https://jkcvhl.com/index.php/jkcvhl/oai
oai:ojs.pkp.sfu.ca:article/6
2022-02-11T11:46:04Z
jkcvhl:KCCR
Rapidly enlarging renal tumor during pregnancy: diagnostic and management dilemma
Tiang, Kor Woi
Ng, Keng Lim
Vega-Vega, Antonio
Wood, Simon
renal cell carcinoma
pregnancy
chromophobe
Kidney Cancer
Urological tumors diagnosed during pregnancy are rare. However, the incidence seems to be increasing largely due to advancements in modern imaging techniques and improved antenatal care. The diagnosis and management of renal tumors during pregnancy poses a dilemma to clinicians. This case report highlights the challenges in managing a large chromophobe renal cell carcinoma in a young primigravida patient. Proper antenatal assessment, a multidisciplinary team approach and appropriate discussion with patient are important determinants to achieve the best clinical outcomes for both the mother and the baby.
Codon Publications
2014-04-22
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/6
10.15586/jkcvhl.2014.6
Journal of Kidney Cancer and VHL; Vol. 1 No. 1 (2014): Journal of Kidney Cancer and VHL; 12-16
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/6/pdf_1
https://jkcvhl.com/index.php/jkcvhl/article/view/6/html_2
Copyright (c) 2015 Kor Wei Tiang, Keng Lim Ng, Antonio Vega-Vega, Simon Wood
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/7
2022-02-11T12:12:31Z
jkcvhl:KCREV
Sunitinib resistance in renal cell carcinoma
Morais, Christudas
renal cell carcinoma
sunitinib
resistance
kidney cancer
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to become the most commonly used first-line therapy for the treatment of metastatic renal cell carcinoma (RCC). Despite significant improvements in progression-free survival, 30% of the patients are intrinsically resistant to sunitinib and the remaining 70% who respond initially will eventually become resistant in 6–15 months. While the molecular mechanisms of acquired resistance to sunitinib have been unravelling at a rapid rate, the mechanisms of intrinsic resistance remain elusive. Combination therapy, sunitinib rechallenge and sequential therapy have been investigated as means to overcome resistance to sunitinib. Of these, sequential therapy appears to be the most promising strategy. This mini review summarises our emerging understanding of the molecular mechanisms, and the strategies employed to overcome sunitinib resistance.
Codon Publications
2014-04-22
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/7
10.15586/jkcvhl.2014.7
Journal of Kidney Cancer and VHL; Vol. 1 No. 1 (2014): Journal of Kidney Cancer and VHL; 1-11
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/7/_1
https://jkcvhl.com/index.php/jkcvhl/article/view/7/html_1
Copyright (c) 2015 Christudas Morais
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/8
2022-02-11T11:33:46Z
jkcvhl:ED
Editor's note
Cancer and VHL, Journal of Kidney
Dear fellow researchers,Welcome to the first issue of the Journal of Kidney Cancer and VHL (JKCVHL).JKCVHL is an open access journal created to fill the vacuum for a specialized journal to disseminate information on the advances in kidney cancer and VHL research. I am confident JKCVHL will fulfil its intended purpose, and will be a leading journal in this field in the days to come.Christudas Morais, MSc, MPhil, PhDEditor
Codon Publications
2014-04-22
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/8
10.15586/jkcvhl.2014.8
Journal of Kidney Cancer and VHL; Vol. 1 No. 1 (2014): Journal of Kidney Cancer and VHL
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/8/pdf_2
https://jkcvhl.com/index.php/jkcvhl/article/view/8/_2
Copyright (c) 2015 Journal of Kidney Cancer and VHL
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/9
2022-02-11T11:22:30Z
jkcvhl:KCREV
Evaluation of steroid hormones and their receptors in development and progression of renal cell carcinoma
Bennett, Nigel C
Rajandram, Retnagowri
Ng, Keng Lim
Gobe, Glenda C
renal cell carcinoma
steroid hormones
retinoids
androgen receptor
kidney cancer
kidney cancer
Steroid hormones and their receptors have important roles in normal kidney biology, and alterations in their expression and function help explain the differences in development of kidney diseases, such as nephrotic syndrome and chronic kidney disease. The distinct gender difference in incidence of renal cell carcinoma (RCC), with males having almost twice the incidence as females globally, also suggests a role for sex hormones or their receptors in RCC development and progression. There was a peak in interest in evaluating the roles of androgen and estrogen receptors in RCC pathogenesis in the late 20th century, with some positive outcomes for RCC therapy that targeted estrogen receptors, especially for metastatic disease. Since that time, however, there have been few studies that look at use of steroid hormone modulators for RCC, especially in the light of new therapies such as the tyrosine kinase inhibitors and new immune therapies, which are having some success for treatment of metastatic RCC. This review summarises past and current literature and attempts to stimulate renewed interest in research into the steroid hormones and their receptors, which might be used to effect, for example, in combination with the other newer targeted therapies for RCC.
Codon Publications
2014-06-15
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/9
10.15586/jkcvhl.2014.9
Journal of Kidney Cancer and VHL; Vol. 1 No. 2 (2014): Journal of Kidney Cancer and VHL; 17-25
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/9/pdf_3
https://jkcvhl.com/index.php/jkcvhl/article/view/9/html_3
Copyright (c) 2015 Nigel Bennett, Retnagowri Rajandram, Keng Lim Ng, Glenda C Gobe
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/10
2022-02-10T11:54:50Z
jkcvhl:KCART
Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
Bayrak, Omer
Sen, Haluk
Bulut, Ersan
Cengiz, Beyhan
Karakok, Metin
Erturhan, Sakip
Seckiner, Ilker
BRAF
EGFR
KRAS
mutations
A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to identify patients who might respond to EGFR-targeted therapy. The aim of this study was to investigate the mutation status of EGFR, KRAS and BRAF in RCC patients. Renal tumors and normal renal samples from forty-eight patients who underwent radical or partial nephrectomy for kidney cancer were used in this study. Histological classification of the tumors was performed according to International Union against Cancer (UICC) / American Joint Committee on Cancer (AJCC) classification. Seventeen patients (48%) had clear-cell RCC, 7 (20%) had chromophobe RCC, and 11 patients (32%) had papillary RCC. DNA isolated from the samples was subjected to melting curve mutation analysis for EGFR, BRAF and KRAS using ABI-3130 DNA sequencer. DNA sequencing analysis of RCC samples, when compared with morphologically normal matched regions, did not show any exon mutations. Our results do not support the notion that EGFR, KRAS and BRAF might be mutated in RCC.
Codon Publications
2014-08-05
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/10
10.15586/jkcvhl.2014.10
Journal of Kidney Cancer and VHL; Vol. 1 No. 4 (2014): Journal of Kidney Cancer and VHL; 40-45
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/10/52
https://jkcvhl.com/index.php/jkcvhl/article/view/10/51
Copyright (c) 2015 Omer Bayrak, Haluk Sen, Ersan Bulut, Beyhan Cengiz, Metin Karakok, Sakip Erturhan, Ilker Seckiner
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/11
2022-02-11T11:04:39Z
jkcvhl:KCREV
The ISUP system of staging, grading and classification of renal cell neoplasia
Samaratunga, Hemamali
Gianduzzo, Troy
Delahunt, Brett
Classification
Grading
International Society of Urological Pathology
ISUP
Kidney cancer
Renal neoplasia
Staging
Urologic Oncology
There have been significant changes in the staging, classification and grading of renal cell neoplasia in recent times. Major changes have occurred in our understanding of extra-renal extension by renal cell cancer and how gross specimens must be handled to optimally display extra-renal spread. Since the 1981 World Health Organization (WHO) classification of renal tumors, in which only a handful of different entities were reported, many new morphological types have been described in the literature, resulting in 50 different entities reported in the 2004 WHO classification. Since 2004, further new entities have been recognized and reported necessitating an update of the renal tumor classification. There have also been numerous grading systems for renal cell carcinoma with Fuhrman grading, the most widely used system. In recent times, the prognostic value and the applicability of the Fuhrman grading system in practice has been shown to be, at best, suboptimal. To address these issues and to recommend reporting guidelines, the International Society of Urological pathology (ISUP) undertook a review of adult renal neoplasia through an international consensus conference in Vancouver in 2012. The conduct of the conference was based upon evidence from the literature and the current practice amongst recognized experts in the field. Working groups selected to deal with key topics evaluated current data and identified points of controversy. A pre-meeting survey of the ISUP membership was followed by the consensus conference at which a formal ballot was taken on each key issue. A 65% majority vote was taken as consensus. This review summarizes the outcome and recommendations of this conference with regards to staging, classification and grading of renal cell neoplasia.
Codon Publications
2014-07-20
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/11
10.15586/jkcvhl.2014.11
Journal of Kidney Cancer and VHL; Vol. 1 No. 3 (2014): Journal of Kidney Cancer and VHL; 26-39
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/11/50
https://jkcvhl.com/index.php/jkcvhl/article/view/11/49
Copyright (c) 2015 Hemamali Samaratunga, Troy Gianduzzo, Brett Delahunt
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/12
2022-02-10T11:44:46Z
jkcvhl:KCREV
Pathological and Clinical Features and Management of Central Nervous System Hemangioblastomas in von Hippel-Lindau Disease
Kanno, Hiroshi
Kobayashi, Natsuki
Nakanowatari, Satoshi
Hemangioblastoma
VHL
von Hippel-Lindau disease
Central nervous system (CNS) hemangioblastoma is the most common manifestation of von Hippel-Lindau (VHL) disease. It is found in 70-80% of VHL patients. Hemangioblastoma is a rare form of benign vascular tumor of the CNS, accounting for 2.0% of CNS tumors. It can occur sporadically or as a familial syndrome. CNS hemangioblastomas are typically located in the posterior fossa and the spinal cord. VHL patients usually develop a CNS hemangioblastoma at an early age. Therefore, they require a special routine for diagnosis, treatment and follow-up. The surgical management of symptomatic tumors depend on many factors such as symptom, location, multiplicity, and progression of the tumor. The management of asymptomatic tumors in VHL patients are controversial since CNS hemangioblastomas grow with intermittent quiescent and rapid-growth phases. Preoperative embolization of large solid hemangioblastomas prevents perioperative hemorrhage but is not necessary in every case. Radiotherapy should be reserved for inoperable tumors. Because of complexities of VHL, a better understanding of the pathological and clinical features of hemangioblastoma in VHL is essential for its proper management.
Codon Publications
2014-08-05
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/12
10.15586/jkcvhl.2014.12
Journal of Kidney Cancer and VHL; Vol. 1 No. 4 (2014): Journal of Kidney Cancer and VHL; 46-55
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/12/54
https://jkcvhl.com/index.php/jkcvhl/article/view/12/53
Copyright (c) 2015 Hiroshi Kanno, Natsuki Kobayashi, Satoshi Nakanowatari
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/13
2022-02-10T11:31:17Z
jkcvhl:KCREV
Tubulocystic Renal Cell Carcinoma: A Rare Renal Tumor
Bhullar, Jasneet Singh
Bindroo, Sandiya
Varshney, Neha
Mittal, Vijay
differential diagnosis
rare renal tumor
tubulocystic renal cell carcinoma
tubulocystic carcinoma
Urologic oncology
Tubulocystic renal cell carcinoma of the kidney is a rare entity with less than one hundred cases reported so far. It was previously considered to have some similarities to various other renal cancers although this tumor has distinct macroscopic, microscopic, and immuno-histochemical features. It is now a well-established entity in renal neoplastic pathology and has been recognized as a distinct entity in the 2012 Vancouver classification of renal tumors. This review aims to give an overview of tubulocystic renal cell carcinoma after extensive literature search using PubMed and CrossRef.
Codon Publications
2014-09-01
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/13
10.15586/jkcvhl.2014.13
Journal of Kidney Cancer and VHL; Vol. 1 No. 5 (2014): Journal of Kidney Cancer and VHL; 56-62
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/13/56
https://jkcvhl.com/index.php/jkcvhl/article/view/13/55
Copyright (c) 2015 Jasneet Singh Bhullar, Sandiya Bindroo, Neha Varshney, Vijay Mittal
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/14
2022-02-10T11:07:00Z
jkcvhl:KCREV
Targeted Therapy for Metastatic Renal Carcinoma: an Update
Donalisio da Silva, Rodrigo
Gustafson, Diedra
Nogueira, Leticia
Werahera, Priya N.
Molina, Wilson R.
Kim, Fernando J.
Kidney Cancer
RCC
targeted therapy
Kidney Cancer
Targeted Therapy
Conventional chemotherapy is associated with poor outcomes in metastatic renal cell carcinoma (RCC). Advances in the understanding of tumor molecular biology and the implementation of new drugs that target these molecular pathways have increased the arsenal against advanced RCC and improved outcomes in these patients. Herein, we briefly describe the latest data on targeted therapies used in the treatment of advanced renal cell carcinoma. Search strategy was performed according to PRISMA guidelines. Abstracts of relevant studies published in PubMed between 2000 and 2014 were analyzed by two authors. Abstracts were selected if they were published in English, data reported was of phase II or III clinical trials, and outcomes followed FDA approval. If consensus between the two authors was achieved, they were included in the review. Key words used were “target therapy” and “metastatic renal cell carcinoma”. The results of the studies analyzed in this review support the benefits of targeted therapy in metastatic RCC. These include improved progression-free survival, overall survival, and quality of life as well as reduced toxicities compared to immunotherapy. The improvement in outcomes in metastatic RCC makes these drugs a preferred option as a primary treatment for these patients.
Codon Publications
2014-10-21
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/14
10.15586/jkcvhl.2014.14
Journal of Kidney Cancer and VHL; Vol. 1 No. 6 (2014): Journal of Kidney Cancer and VHL; 63-73
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/14/60
https://jkcvhl.com/index.php/jkcvhl/article/view/14/59
Copyright (c) 2015 Rodrigo Donalisio da Silva, Diedra Gustafson, Leticia Nogueira, Priya N. Werahera, Wilson R Molina, Fernando J. Kim
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/18
2022-02-10T10:50:34Z
jkcvhl:KCREV
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?
Amin, Asim
White, Richard L
IL-2
interleukin-2
immunomodulation
immunotherapy
renal cell carcinoma
Modulation of the immune response plays an important role in the natural history of renal cell carcinoma. Spontaneous regression of metastases has been well documented in a small percentage of patients after they undergo de-bulking nephrectomy without any additional systemic intervention. The only logical explanation for these observations is “resetting” of the balance between tumor and the host immune system that, having been overwhelmed by the tumor burden, is able to function better after tumor de-bulking. Attempts to modulate the activity of the immune system “on demand” have included the use of vaccines, cytokines/lymphokines, adoptive cell transfer, monoclonal antibodies and most recently manipulation of immune checkpoint inhibitors. Here we review the data for infusional interleukin-2 in the management of advanced renal cell carcinoma and its role in current clinical practice.
Codon Publications
2014-11-23
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/18
10.15586/jkcvhl.2014.18
Journal of Kidney Cancer and VHL; Vol. 1 No. 7 (2014): Journal of Kidney Cancer and VHL; 74-83
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/18/62
https://jkcvhl.com/index.php/jkcvhl/article/view/18/61
Copyright (c) 2015 Asim Amin, Richard L White
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/19
2022-02-10T10:41:28Z
jkcvhl:KCREV
Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?
Teixeira, Ana L
Dias, Francisca
Gomes, Monica
Fernandes, Mara
Medeiros, Rui
MicroRNA
renal cell carcinoma
extracellular vescicles
Renal cell carcinoma (RCC) is a lethal urological cancer, with incidence and mortality rates increasing by 2-3% per decade. The lack of standard screening tests contributes to the fact that one-third of patients are diagnosed with locally invasive or metastatic disease. Moreover, 20-40% of RCC patients submitted to surgical nephrectomy will develop metastasis. MicroRNAs (miRNAs) are small non-coding RNAs responsible for gene regulation at a post-transcriptional level. It is accepted that they are deregulated in cancer and can influence tumor development. Thus, miRNAs are promising RCC biomarkers, since they can be detected using non-invasive methods. They are highly stable and easier to quantify in circulating biofluids. The elevated miRNA stability in circulating samples may be the consequence of their capacity to circulate inside of extracellular microvesicles (EMVs), for example, the exosomes. The EMVs are bilayered membrane vesicles secreted by all cell types. They can be released in the interstitial space or into circulating biofluids, which allows the travelling, binding and entrance of these vesicles in receptor cells. This type of cell communication can shuttle bioactive molecules between cells, allowing the horizontal transference of genetic material. In this review, we focus on circulating miRNAs (miR-210, miR-1233, miR-221, miR-15a, miR-451, miR-508, miR-378) in the biofluids of RCC patients and attempt to establish the diagnostic and prognostic accuracy, their synergic effects, and the pathways involved in RCC biology.
Codon Publications
2014-12-24
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/19
10.15586/jkcvhl.2014.19
Journal of Kidney Cancer and VHL; Vol. 1 No. 8 (2014): Journal of Kidney Cancer and VHL; 84-98
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/19/64
https://jkcvhl.com/index.php/jkcvhl/article/view/19/63
Copyright (c) 2015 Ana L Teixeira, Francisca Dias, Mónica Gomes, Mara Fernandes, Rui Medeiros
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/20
2022-02-10T10:15:54Z
jkcvhl:KCART
Clinicians’ Real World Perceptions of Pre-Nephrectomy Diagnostic Biopsy Performance as a Driver of Reduction in Unnecessary Surgeries in Renal Tumors
Fahy, Kristin
Augustine, Lauren
Sanden, Mats O.
Wassman, E. Robert
Kidney Cancer
Pre-nephrectomy biopsy
oncocytoma
chromophobe RCC
RCC
microRNA diagnostics
Kidney Cancer
Oncology
Pre-operative biopsy
Operative removal of oncocytomas is generally unnecessary, but not infrequent in the context of renal masses. The infrequent use of pre-nephrectomy biopsies is a function of historical limitations of histopathological differential diagnosis in this setting. Assessment of clinicians’ receptiveness to a novel molecular diagnostic approach to this challenge was undertaken by means of a survey vehicle administered to 102 practicing urologists and pathologists who met inclusion criteria related to their actual clinical activity. Survey results supported the previously reported observations on misdiagnosis with urologists’ reported rates of 25% inconclusive results, and an additional 17% disagree with the final surgical diagnosis. The self-reported rate of 9% for pre-operative biopsies was comparable to prior reports, but 39% of urologists who are not currently performing pre-operative biopsies expressed interest in introducing them into their practice for this purpose with an improved diagnostic. Almost all urologists (94%) felt it important not to resect benign oncocytomas and 62% indicated they would use a test which improved the ability to sub-type renal tumors pre-operatively. The level of performance benchmark of the unidentified prototypic microRNA-based diagnostic as reported previously in the literature was deemed sufficient to change care in these cases by 73%. Overall they predicted a 38% rate of biopsies and resulting increases in decisions to forgo nephrectomy or to perform only partial nephrectomy. Pathologists also expressed support for the use of this technology in the context of inadequate specimens and for improved sub-typing of these tumors in inconclusive cases.
Codon Publications
2015-01-18
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
https://jkcvhl.com/index.php/jkcvhl/article/view/20
10.15586/jkcvhl.2015.20
Journal of Kidney Cancer and VHL; Vol. 2 No. 1 (2015): Journal of Kidney Cancer and VHL; 1-14
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/20/68
https://jkcvhl.com/index.php/jkcvhl/article/view/20/67
https://jkcvhl.com/index.php/jkcvhl/article/view/20/238
10.15586/jkcvhl.2015.20.4
Copyright (c) 2015 Kristin Fahy, Lauren Augustine, Mats O Sanden, E. Robert Wassman
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/21
2022-02-10T10:06:57Z
jkcvhl:KCREV
Gramicidin A: A New Mission for an Old Antibiotic
David, Justin M.
Rajasekaran, Ayyappan K.
Gramicidin
ionophore
renal cell carcinoma
Gramicidin A (GA) is a channel-forming ionophore that renders biological membranes permeable to specific cations which disrupts cellular ionic homeostasis. It is a well-known antibiotic, however it’s potential as a therapeutic agent for cancer has not been widely evaluated. In two recently published studies, we showed that GA treatment is toxic to cell lines and tumor xenografts derived from renal cell carcinoma (RCC), a devastating disease that is highly resistant to conventional therapy. GA was found to possess the qualities of both a cytotoxic drug and a targeted angiogenesis inhibitor, and this combination significantly compromised RCC growth in vitro and in vivo. In this review, we summarize our recent research on GA, discuss the possible mechanisms whereby it exerts its anti-tumor effects, and share our perspectives on the future opportunities and challenges to the use of GA as a new anticancer agent.
Codon Publications
2015-01-18
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/21
10.15586/jkcvhl.2015.21
Journal of Kidney Cancer and VHL; Vol. 2 No. 1 (2015): Journal of Kidney Cancer and VHL; 15-24
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/21/66
https://jkcvhl.com/index.php/jkcvhl/article/view/21/65
Copyright (c) 2015 Justin M David, Ayyappan K Rajasekaran
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/22
2022-02-10T10:26:09Z
jkcvhl:KCART
Glutathione-S-transferase-pi (GST-pi) expression in renal cell carcinoma
Kaprilian, Christina
Horti, Maria
Kandilaris, Kosmas
Skolarikos, Andreas
Trakas, Nikolaos
Kastriotis, Ioannis
Deliveliotis, Charalambos
Glutathione-s-transferase
GST-pi
immunohistochemistry
multidrug resistance
renal cell carcinoma
Kidney Cancer
Oncology
Multidrug resistance correlates with unfavourable treatment outcomes in numerous cancers including renal cell carcinoma. The expression and clinical relevance of Glutathione-S-transferase-pi (GST-pi), a multidrug resistance factor, in kidney tumors remain controversial. We analyzed the expression of GST-pi in 60 formalin-fixed, paraffin-embedded renal cell carcinoma samples by immunohistochemistry and compared them with matched normal regions of the kidney. A significantly higher expression of GST-pi was observed in 87% of clear cell carcinoma and 50% of papillary subtypes. GST-pi expression did not correlate with tumor grade or patient survival. GST-pi is unlikely to be a prognostic factor for renal cell carcinoma. However, further studies with large number of samples are warranted to establish the role of GST-pi, if any, in intrinsic or acquired resistance of renal cell carcinoma to conventional treatments.
Codon Publications
2015-02-22
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/vnd.ms-excel
https://jkcvhl.com/index.php/jkcvhl/article/view/22
10.15586/jkcvhl.2015.22
Journal of Kidney Cancer and VHL; Vol. 2 No. 1 (2015): Journal of Kidney Cancer and VHL; 25-29
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/22/70
https://jkcvhl.com/index.php/jkcvhl/article/view/22/69
https://jkcvhl.com/index.php/jkcvhl/article/view/22/239
10.15586/jkcvhl.2015.22.6
Copyright (c) 2015 Christina Kaprilian, Maria Horti, Kosmas Kandilaris, Andreas Skolarikos, Nikolaos Trakas, Ioannis Kastriotis, Charalambos Deliveliotis
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/23
2022-02-08T11:57:45Z
jkcvhl:KCREV
Review of robot-assisted partial nephrectomy in modern practice
Potretzke, Aaron M.
Weaver, John
Benway, Brian M.
Neoplasm
Nephrectomy
Partial nephrectomy
Postoperative complications
robot-assisted partial nephrectomy
Partial nephrectomy (PN) is currently the standard treatment for T1 renal tumors. Minimally invasive PN offers decreased blood loss, shorter length of stay, rapid convalescence, and improved cosmesis. Due to the challenges inherent in laparoscopic partial nephrectomy, its dissemination has been stifled. Robot-assisted partial nephrectomy (RAPN) offers an intuitive platform to perform minimally invasive PN. It is one of the fastest growing robotic procedures among all surgical subspecialties. RAPN continues to improve upon the oncological and functional outcomes of renal tumor extirpative therapy. Herein, we describe the surgical technique, outcomes, and complications of RAPN.
Codon Publications
2015-04-04
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/23
10.15586/jkcvhl.2015.23
Journal of Kidney Cancer and VHL; Vol. 2 No. 2 (2015): Journal of Kidney Cancer and VHL; 30-44
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/23/72
https://jkcvhl.com/index.php/jkcvhl/article/view/23/71
Copyright (c) 2015 Aaron M Potretzke, John Weaver, Brian M Benway
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/24
2022-02-10T09:21:36Z
jkcvhl:KCREV
Present and future perspectives on immunotherapy for advanced renal cell carcinoma: Going to the core or beating around the bush?
Kawashima, Hidenori
Kimura, Yasunori
Renal cell carcinoma
immunotherapy
cytokine
peptide-based vaccine
tumor antigen
immune checkpoint inhibitor
Metastatic lesions of renal cell carcinoma (RCC) occasionally regress spontaneously after surgical removal of the primary tumor. Although this is an exceptionally rare occurrence, RCC has thus been postulated to be immunogenic. Immunotherapies, including cytokine therapy, peptide-based vaccines, and immune checkpoint inhibitors have therefore been used to treat patients with advanced, metastatic RCC. We review the history, trends, and recent progress in immunotherapy for advanced RCC and discuss future perspectives, with consideration of our experimental work on galectin 9 and PINCH as promising specific immunotherapy targets.
Codon Publications
2015-04-04
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/24
10.15586/jkcvhl.2015.24
Journal of Kidney Cancer and VHL; Vol. 2 No. 2 (2015): Journal of Kidney Cancer and VHL; 55-63
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/24/76
https://jkcvhl.com/index.php/jkcvhl/article/view/24/75
Copyright (c) 2015 Hidenori Kawashima, Yasunori Kimura
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/25
2022-02-08T11:51:21Z
jkcvhl:KCCR
Metastatic renal cell carcinoma from a native kidney of a renal transplant patient diagnosed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) biopsy
Alastal, Yaseen
Hammad, Tariq A
Rafiq, Ehsan
Nawras, Mohamad
Alaradi, Osama
Nawras, Ali
EUS guided FNA
Fine needle aspiration biopsy
Renal transplant
Kidney Cancer
Oncology
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) biopsy sampling of enlarged lymph nodes is increasingly used to diagnose metastatic tumors, especially of the gastrointestinal tract and the lungs. Herein, we describe the diagnosis of metastatic renal cell carcinoma from a native kidney of a 54 year-old male patient, who had a 5-years history of renal transplant, by EUS-FNA of mediastinal and celiac lymph nodes. Histological and immunohistochemical findings confirmed the origin of metastatic tumor. EUS-FNA with proper cytological evaluation can be useful in the diagnosis of metastatic renal cell carcinoma in renal transplant patients.
Codon Publications
2015-04-20
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/25
10.15586/jkcvhl.2015.25
Journal of Kidney Cancer and VHL; Vol. 2 No. 2 (2015): Journal of Kidney Cancer and VHL; 70-74
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/25/80
https://jkcvhl.com/index.php/jkcvhl/article/view/25/79
Copyright (c) 2015 Yaseen Alastal, Tariq A Hammad, Ehsan Rafiq, Mohamad Nawras, Osama Alaradi, Ali Nawras
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/26
2022-02-08T12:04:53Z
jkcvhl:KCREV
Renal functional outcomes after surgery for renal cortical tumors
Lascano, Danny
Finkelstein, Julia B.
DeCastro, G. Joel
McKiernan, James M.
Partial nephrectomy
Renal function
Renal cortical tumors
Historically, radical nephrectomy represented the gold standard for the treatment of small (≤ 4cm) as well as larger renal masses. Recently, for small renal masses, the risk of ensuing chronic kidney disease and end stage renal disease has largely favored nephron-sparing surgical techniques, mainly partial nephrectomy. In this review, we surveyed the literature on renal functional outcomes after partial nephrectomy for renal tumors. The largest randomized control trial comparing radical and partial nephrectomy failed to show a survival benefit for partial nephrectomy. With regards to overall survival, surgically induced chronic kidney disease (GFR < 60 ml/min/ 1.73m2) caused by nephrectomy might not be as deleterious as medically induced chronic kidney disease. In evaluating patients who underwent donor nephrectomy, transplant literature further validates that surgically induced reductions in GFR may not affect patient survival, unlike medically induced GFR declines. Yet, because patients who present with a renal mass tend to be elderly with multiple comorbidities, many develop a mixed picture of medically, and surgically-induced renal disease after extirpative renal surgery. In this population, we believe that nephron sparing surgery optimizes oncological control while protecting renal function.
Codon Publications
2015-04-04
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/26
10.15586/jkcvhl.2015.26
Journal of Kidney Cancer and VHL; Vol. 2 No. 2 (2015): Journal of Kidney Cancer and VHL; 45-54
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/26/74
https://jkcvhl.com/index.php/jkcvhl/article/view/26/73
Copyright (c) 2015 Danny Lascano, Julia B Finkelstein, G. Joel DeCastro, James M McKiernan
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/27
2022-02-10T09:25:21Z
jkcvhl:KCREV
Tumor Enucleation for Renal Cell Carcinoma
Smith, Zachary L.
Malkowicz, S. Bruce
Nephron-sparing surgery
Tumor enucleation
Renal cell carcinoma
The increased number of small renal masses (SRMs) detected annually has led to a rise in the use of nephron-sparing surgery (NSS). These techniques aim to preserve the largest amount of healthy renal tissue possible while maintaining the same oncologic outcomes as radical nephrectomy (RN). Additionally, partial nephrectomy (PN) has been linked to a lower risk of chronic kidney disease, cardiovascular morbidity, and mortality when compared to RN. There has been continual progress toward resecting less renal parenchyma. While the predominant surgical method of performing NSS is through traditional PN, simple enucleation (SE) of the tumor has increased in popularity over recent years. SE is a technique that aims to preserve the maximal amount of renal parenchyma possible by utilizing the renal tumor pseudocapsule to bluntly separate the lesion from its underlying parenchyma, offering the smallest possible margin of excised healthy renal tissue. Several studies have demonstrated the oncological safety of SE compared with PN in the treatment of SRMs, with lower overall incidence of positive surgical margins. Additionally, SE has been shown to have similar 5- and 10-year progression-free and cancer-specific survival as PN. We present a review of the literature and an argument for SE to be a routine consideration in the treatment of all renal tumors amenable to NSS.
Codon Publications
2015-04-04
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/27
10.15586/jkcvhl.2015.27
Journal of Kidney Cancer and VHL; Vol. 2 No. 2 (2015): Journal of Kidney Cancer and VHL; 64-69
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/27/78
https://jkcvhl.com/index.php/jkcvhl/article/view/27/77
Copyright (c) 2015 Zachary L Smith, Bruce Malkowicz
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/28
2022-02-10T09:30:44Z
jkcvhl:KCREV
Management of metastatic renal cell carcinoma – mini review
Bharthuar, Anubha
Pandey, Himanshu
Sood, Swapan
Metastatic renal cell carcinoma
Prognostic models
Targeted therapy
The management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the last decade. A number of different systemic molecular targeted agents that have been recently approved have improved the survival of patients with mRCC. This mini-review focuses on the implementation of multi-modality therapy in the management of mRCC and the approved indications of the various available novel agents. These novel agents have expanded our armamentarium and improved clinical outcomes of this challenging disease that has considerable biological heterogeneity and clinical variability.
Codon Publications
2015-05-05
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/28
10.15586/jkcvhl.2015.28
Journal of Kidney Cancer and VHL; Vol. 2 No. 2 (2015): Journal of Kidney Cancer and VHL; 75-83
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/28/82
https://jkcvhl.com/index.php/jkcvhl/article/view/28/81
Copyright (c) 2015 Anubha Bharthuar, Himanshu Pandey, Swapan Sood
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/29
2022-02-06T12:52:36Z
jkcvhl:KCREV
Malignant renal tumors in children
Lee, Justin Scott
Sanchez, Thomas Ray
Wootton-Gorges, Sandra
Malignant rhabdoid tumor
Nephroblastomatosis
Renal medullary carcinoma
Tumors in children
Wilms tumor
kidney cancer
oncology
Renal malignancies are common in children. While the majority of malignant renal masses are secondary to Wilms tumor, it can be challenging to distinguish from more aggressive renal masses. For suspicious renal lesions, it is crucial to ensure prompt diagnosis in order to select the appropriate surgical procedure and treatment. This review article will discuss the common differential diagnosis that can be encountered when evaluating a suspicious renal mass in the pediatric population. This includes clear cell sarcoma of the kidney, malignant rhabdoid tumor, renal medullary carcinoma and lymphoma. Copyright: The Authors.
Codon Publications
2015-05-10
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/29
10.15586/jkcvhl.2015.29
Journal of Kidney Cancer and VHL; Vol. 2 No. 3 (2015): Journal of Kidney Cancer and VHL; 84-89
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/29/84
https://jkcvhl.com/index.php/jkcvhl/article/view/29/83
Copyright (c) 2015 Justin Scott Lee, Thomas Ray Sanchez, Sandra Wootton-Gorges
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/33
2022-02-06T13:05:07Z
jkcvhl:KCREV
The epigenetic landscape of clear-cell renal cell carcinoma
Kluzek, Katarzyna
Bluyssen, Hans A
Wesoly, Joanna
clear-cell renal cell carcinoma (ccRCC)
tumor suppressor gene (TSG)
epigenetic modification
epigenetic biomarkers
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of all kidney tumors. During the last few years, epigenetics has emerged as an important mechanism in ccRCC pathogenesis. Recent reports, involving large-scale methylation and sequencing analyses, have identified genes frequently inactivated by promoter methylation and recurrent mutations in genes encoding chromatin regulatory proteins. Interestingly, three of detected genes (PBRM1, SETD2 and BAP1) are located on chromosome 3p, near the VHL gene, inactivated in over 80% ccRCC cases. This suggests that 3p alterations are an essential part of ccRCC pathogenesis. Moreover, most of the proteins encoded by these genes cooperate in histone H3 modifications. The aim of this review is to summarize the latest discoveries shedding light on deregulation of chromatin machinery in ccRCC. Newly described ccRCC-specific epigenetic alterations could potentially serve as novel diagnostic and prognostic biomarkers and become an object of novel therapeutic strategies.
Codon Publications
2015-05-28
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/33
10.15586/jkcvhl.2015.33
Journal of Kidney Cancer and VHL; Vol. 2 No. 3 (2015): Journal of Kidney Cancer and VHL; 90-104
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/33/86
https://jkcvhl.com/index.php/jkcvhl/article/view/33/85
Copyright (c) 2015 Katarzyna Kluzek, Hans Antonius Bluyssen, Joanna Wesoly
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/34
2022-02-06T13:41:58Z
jkcvhl:KCREV
Percutaneous Cryoablation for Renal Cell Carcinoma
Maria, Tsitskari
Georgiades, Christos
Cryoablation
Cryoprobe
Radio frequency ablation
renal cell carcinoma
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. Nephron sparing resection (partial nephrectomy) has been the “gold standard” for the treatment of resectable disease. With the widespread use of cross sectional imaging techniques, more cases of renal cell cancers are detected at an early stage, i.e. stage 1A or 1B. This has provided an impetus for expanding the nephron sparing options and especially, percutaneous ablative techniques. Percutaneous ablation for RCC is now performed as a standard therapeutic nephron-sparing option in patients who are poor candidates for resection or when there is a need to preserve renal function due to comorbid conditions, multiple renal cell carcinomas, and/or heritable renal cancer syndromes. During the last few years, percutaneous cryoablation has been gaining acceptance as a curative treatment option for small renal cancers. Clinical studies to date indicate that cryoablation is a safe and effective therapeutic method with acceptable short and long term outcomes and with a low risk, in the appropriate setting. In addition it seems to offer some advantages over radio frequency ablation (RFA) and other thermal ablation techniques for renal masses.
Codon Publications
2015-06-09
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/34
10.15586/jkcvhl.2015.34
Journal of Kidney Cancer and VHL; Vol. 2 No. 3 (2015): Journal of Kidney Cancer and VHL; 105-113
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/34/88
https://jkcvhl.com/index.php/jkcvhl/article/view/34/90
Copyright (c) 2015 Tsitskari Maria, Christos Georgiades
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/35
2022-02-06T13:47:03Z
jkcvhl:KCREV
Pathology of the Nervous System in Von Hippel-Lindau Disease
Vortmeyer, Alexander O.
Alomari , Ahmed K.
Endolymphatic sac tumors
Hemangioblastoma
Nervous system
Progenitor cells
VHL syndrome
Von Hippel-Lindau (VHL) disease is a tumor syndrome that frequently involves the central nervous system (CNS). It is caused by germline mutation of the VHL gene. Subsequent VHL inactivation in selected cells is followed by numerous well-characterized molecular consequences, in particular, activation and stabilization of hypoxia-inducible factors HIF1 and HIF2. The link between VHL gene inactivation and tumorigenesis remains poorly understood. Hemangioblastomas are the most common manifestation in the CNS; however, CNS invasion by VHL disease-associated endolymphatic sac tumors or metastatic renal cancer also occur, and their differentiation from primary hemangioblastoma may be challenging. Finally, in this review, we present recent morphologic insights on the developmental concept of VHL tumorigenesis which is best explained by pathologic persistence of temporary embryonic progenitor cells.
Codon Publications
2015-06-11
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/35
10.15586/jkcvhl.2015.35
Journal of Kidney Cancer and VHL; Vol. 2 No. 3 (2015): Journal of Kidney Cancer and VHL; 114-129
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/35/91
https://jkcvhl.com/index.php/jkcvhl/article/view/35/92
Copyright (c) 2015 Alexander O Vortmeyer
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/36
2021-10-27T11:56:37Z
jkcvhl:KCCR
Displacement of the Spleen Mimicking Renal Cell Cancer Recurrence Post-Nephrectomy: A Case Report
Emanuels, Carolina S.
Timmerman, Krista D.
Aijaz, Tabish
Nguyen, Thu-Cuc
Jest, Nathaniel
Drane, Walter E.
Gilbert, Scott M.
Crispen, Paul L.
Su, Li-Ming
Deitte, Lori A.
Dang, Long H.
imaging
kidney cancer
RCC recurrence
renal fossa
spleen
technetium-99m sulfur colloid scan
kidney cancer
imaging
Local regional recurrence of renal cell cancer post-nephrectomy most often occurs within three years after surgery. Post-nephrectomy, many processes may mimic RCC recurrence. We present the case of a 75 year-old Caucasian male patient with a mass in his renal fossa post-nephrectomy for renal cell cancer, suggesting local recurrence. Use of the technetium-99m sulfur colloid scan showed that the mass was his spleen which had been displaced into the renal fossa. With high index of suspicion, characterization of these processes as splenic in origin would prevent subjecting patients to risks of biopsy or even surgery.
Codon Publications
2015-06-20
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/36
10.15586/jkcvhl.2015.36
Journal of Kidney Cancer and VHL; Vol. 2 No. 3 (2015): Journal of Kidney Cancer and VHL; 130-133
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/36/94
https://jkcvhl.com/index.php/jkcvhl/article/view/36/93
Copyright (c) 2015 Long H Dang
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/37
2021-10-27T12:13:33Z
jkcvhl:KCCR
Collecting Duct Renal Cell Carcinoma Found to Involve the Collecting System During Partial Nephrectomy: A Case Report
Harbin, Andrew C
Styskel, Brett A
Patel, Viren
Wang, He
Eun, Daniel D
collecting duct carcinoma
renal cell carcinoma
partial nephrectomy
collecting system
Kidney cancer
Collecting duct carcinoma (CDC) is a rare and aggressive form of renal cell carcinoma (RCC) arising from the principal cells of the collecting duct. One third of cases present with metastatic disease, but many present in a manner similar to conventional RCC or urothelial carcinoma (UC). We discuss a case of CDC which presented as a small mass at the cortico-medullary junction, and was discovered at robotic partial nephrectomy (RPN) to be grossly involving the collecting system. A 62-year-old man presented with a small renal mass suspicious for RCC, which was found on computed tomography (CT) after an episode of gross hematuria. After thorough workup, RPN was attempted; however, intraoperatively the mass was found to be involving the collecting system. Radical nephroureterectomy was performed, and the pathology report revealed CDC. CDC is a rare and aggressive form of RCC. While many cases are metastatic at diagnosis, most patients present with the incidental finding of a small renal mass. There are no reports of a CDC involving the collecting system at RPN after negative ureteroscopy preoperatively. The adjuvant therapeutic options for CDC are limited, and long term survival is poor.
Codon Publications
2015-06-24
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/37
10.15586/jkcvhl.2015.37
Journal of Kidney Cancer and VHL; Vol. 2 No. 3 (2015): Journal of Kidney Cancer and VHL; 134-139
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/37/96
https://jkcvhl.com/index.php/jkcvhl/article/view/37/95
Copyright (c) 2015 Andrew C Harbin
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/38
2021-10-25T10:44:39Z
jkcvhl:KCART
Revealing a Pre-neoplastic Renal Tubular Lesion by p-S6 Protein Immunohistochemistry after Rat Exposure to Aristolochic Acid
Gruia, Alexandra
Gazinska, Patrycja
Herman, Diana
Ordodi, Valentin
Tatu, Calin
Mantle, Peter
Aristolochic acid
Balkan nephropathy
Ochratoxin A
Ribosomal phospho-S6 protein
Urothelial tumours
Kidney Cancer
Aristolochic acid (AA) has, in the last decade, become widely promoted as the cause of the Balkan endemic nephropathy and associated renal or urothelial tumours, although without substantial focal evidence of the quantitative dietary exposure via bread in specific households in hyperendemic villages. Occasional ethnobotanical use of Aristolochia clematitis might be a source of AA, and Pliocene lignite contamination of well-water is also a putative health risk factor. The aim of this study was two-fold: to verify if extracts of A. clematitis and Pliocene, or AA by itself, could induce the development of renal or urothelial tumours, and to test the utility of the ribosomal protein p-S6 to identify preneoplastic transformation. Rats were given extracts of A. clematitis in drinking water or AA I, by gavage. After seven months, renal morphology was studied using conventional haematoxylin and eosin and immunohistochemistry for ribosomal p-S6 protein. Plant extracts (cumulative AA approximately 1.8 g/kg b.w.) were tolerated and caused no gross pathology or renal histopathological change, with only faint diffuse p-S6 protein (except in the papilla) as in controls. Cumulative AA I (150 mg/kg b.w. given over 3 days) was also tolerated for seven months by all recipients, without gross pathology or kidney tumours. However, p-S6 protein over-expression was consistent particularly within the renal papilla. In one case given AA I, intense p-S6 protein staining of a proximal tubule fragment crucially matched the pre-neoplastic histology in an adjacent kidney section. We briefly discuss these findings, which compound uncertainty concerning the cause of the renal or upper urinary tract tumours of the Balkan endemic nephropathy.
Codon Publications
2015-09-08
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/38
10.15586/jkcvhl.2015.38
Journal of Kidney Cancer and VHL; Vol. 2 No. 4 (2015): Journal Of Kidney Cancer and VHL; 153-162
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/38/100
https://jkcvhl.com/index.php/jkcvhl/article/view/38/101
Copyright (c) 2015 Alexandra Gruia, Patrycja Gazinska, Diana Herman, Valentin Ordodi, Calin Tatu, Peter George Mantle
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/40
2021-10-22T11:50:27Z
jkcvhl:KCREV
MicroRNAs in clear cell renal cell carcinoma: biological functions and applications
Aguiari, Gianluca
MicroRNA
renal cell carcinoma
kidney cancer
VHL
MicroRNAs (miRs) are small noncoding RNAs that govern many biological processes. They frequently acquire a gain or a loss of function in cancer and hence play a causative role in the development and progression of neoplasms. They could be used as biomarkers to improve our knowledge on diagnosis, prognosis and drug resistance, and to attempt therapeutic approaches in several types of cancer including clear cell renal cell carcinoma (ccRCC). ccRCC is the most predominant subtype of RCC that accounts for about 90% of all renal cancers. Since ccRCC is generally asymptomatic until very late, it is difficult to diagnose early. Moreover, in the absence of preventive treatments for metastatic ccRCC after surgical resection of the primary cancer, predictive prognostic biomarkers are needed in order to achieve appropriate therapies. Herein the role of miRs in the biology of ccRCC and the potential applications of these molecules are discussed. Moreover, future applications in the diagnostic and prognostic field, as well as their impact on drug response and therapeutic targets are also explored. Their use in clinical practice as molecular biomarkers alone, or in combination with other biological markers could accelerate progress, help design personalized therapies, limit side effects, and improve quality of life of ccRCC patients.
Codon Publications
2015-08-23
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/40
10.15586/jkcvhl.2015.40
Journal of Kidney Cancer and VHL; Vol. 2 No. 4 (2015): Journal Of Kidney Cancer and VHL; 140-152
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/40/98
https://jkcvhl.com/index.php/jkcvhl/article/view/40/97
Copyright (c) 2015 Gianluca Aguiari
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/41
2021-10-23T05:05:11Z
jkcvhl:KCREV
Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma
Ashouri, Kenan
Mohseni, Sophia
Tourtelot, John
Sharma, Pranav
Spiess, Philippe E.
Clear cell carcinoma
Hereditary cancer syndrome
Kidney cancer
Management
Renal cell carcinoma
VHL
von-Hippel Lindau
Von Hippel-Lindau syndrome (VHLS) is a rare hereditary neoplastic disorder caused by mutations in the vhl gene leading to the development of tumors in several organs including the central nervous system, pancreas, kidneys, and reproductive organs. Manifestations of VHLS can present at different ages based on the affected organ and subclass of disease. In the subclasses of VHLS that cause renal disease, renal involvement typically begins closer to the end of the second decade of life and can present in different ways ranging from simple cystic lesions to solid tumors. Mutations in vhl are most often associated with clear cell renal carcinoma, the most common type of renal cancer, and also play a major role in sporadic cases of clear cell renal carcinoma. The recurrent, multifocal nature of this disease presents difficult challenges in the long-term management of patients with VHLS. Optimization of renal function warrants the use of several different approaches common to the management of renal carcinoma such as nephron-sparing surgery, enucleation, ablation, and targeted therapies. In VHLS, renal lesions of 3 cm or bigger are considered to have metastatic potential and even small lesions often harbor malignancy. Many of the aspects of management revolve around optimizing both oncologic outcome and long-term renal function. As new surgical strategies and targeted therapies develop, the management of this complex disease evolves. This review will discuss the key aspects of the current management of VHLS.
Codon Publications
2015-09-25
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/41
10.15586/jkcvhl.2015.41
Journal of Kidney Cancer and VHL; Vol. 2 No. 4 (2015): Journal Of Kidney Cancer and VHL; 163-173
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/41/103
https://jkcvhl.com/index.php/jkcvhl/article/view/41/102
Copyright (c) 2015 Kenan Ashouri, Sophia Mohseni, John Tourtelot, Pranav Sharma, Philippe E Spiess
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/42
2021-10-27T06:03:54Z
jkcvhl:KCART
18F-FDG PET-CT Findings Before and After Laparoscopic Cryoablation of Small Renal Mass: An Initial Report
Lagerveld, Brunolf W.
Sivro, Ferida
van der Zee, Johan A.
Baars, Phillippe C.
Cryoablation
Renal Cancer
Renal Mass
PET-CT
Kidney Cancer
Cryoablation
The aim of this study was to describe the characteristics of positron emission tomography (PET) molecular imaging combined with low-dose computed tomography (CT) in small renal mass (SRM) treated with cryoablation (CA). Currently, treatment success is defined by the absence of contrast enhancement at CT. However, the use of contrast is relatively contraindicated in patients with renal function impairment, mandating alternative follow-up strategies. Several reasons were identified as criteria for performing PET-CT before and/or after SRM-CA in 9 patients, and the results were retrospectively studied. The histology revealed renal cell carcinoma in 7 patients and oncocytoma in 2 patients. In 6 patients, a PET-CT was performed before and after CA. In one patient, the PET-CT was performed only before CA and in 2 patients only after CA. Before CA, clearly there was metabolic uptake of fluorine-18 fluorodeoxyglucose (18F-FDG) in the SRM in all patients. Following CA, the absence of 18F-FDG uptakes in the SRM could clearly be noticed. However, the tracer cannot always be distinguished from focal recurrence or reactive inflammatory tissue. In one patient, asymptomatic metastatic bone lesions were noticed when performing PET-CT at follow-up. This pilot study with 18F-FDG PET-CT for the follow-up of SRM cryosurgery showed that 18F-FDG PET-CT imaging could be used to characterize cryoablative tissue injury at different times after CA.
Codon Publications
2015-12-10
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/42
10.15586/jkcvhl.2015.42
Journal of Kidney Cancer and VHL; Vol. 2 No. 4 (2015): Journal Of Kidney Cancer and VHL; 174-186
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/42/106
https://jkcvhl.com/index.php/jkcvhl/article/view/42/105
Copyright (c) 2015 Brunolf Walther Lagerveld, MD, PhD
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/43
2021-10-25T05:49:13Z
jkcvhl:KCREV
The Role of Everolimus in Renal Cell Carcinoma
Meskawi, Malek
Valdivieso, Roger
Dell'Oglio, Paolo
Trudeau, Vincent
Larcher, Alessandro
Karakiewicz, Pierre I.
everolimus
kidney cancer
mTOR
renal cell carcinoma.
Everolimus (RAD001) is an orally administered agent that inhibits the mammalian target of rapamycin serine-threonine kinase. A phase III pivotal trial on everolimus, published in 2008, provided the first evidence for the efficacy of sequential therapy for patients with metastatic clear cell renal cell carcinoma (RCC). In this study, everolimus was used after failure of one or several previous lines of therapy, and it demonstrated a 3-month survival benefit relative to placebo. Currently, based on the level 1 evidence, everolimus represents the molecule of choice for third-line therapy after failure of previous two tyrosine kinase inhibitors (TKIs). However, second-line use after failure of one TKI is challenged by two new molecules (nivolumab and cabozantinib), which proved to have better efficacy with similar toxicity profile. In non-clear cell metastatic RCC, the current evidence recommends everolimus as a second-line therapy after failure of previous first-line sunitinib.
Codon Publications
2015-12-30
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/43
10.15586/jkcvhl.2015.43
Journal of Kidney Cancer and VHL; Vol. 2 No. 4 (2015): Journal Of Kidney Cancer and VHL; 187-194
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/43/109
https://jkcvhl.com/index.php/jkcvhl/article/view/43/108
Copyright (c) 2015 Malek Meskawi, Roger Valdivieso, Paolo Dell’Oglio, Vincent Trudeau, Alessandro Larcher, Pierre I Karakiewicz
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/44
2021-10-25T06:02:44Z
jkcvhl:KCREV
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
Azijli, Kaamar
Gotink, Kristy J.
Verheul, Henk M.W.
Drug resistance
Kidney cancer
Lysosomes
Lysosomal sequestration
Renal cell cancer
Sunitinib resistance
Renal cell carcinoma
VHL mutation
Renal cell carcinoma (RCC) is a highly vascularized tumor type, which is often associated with inactivated mutations in the von Hippel-Lindau gene that drives proangiogenic signaling pathways. As such, new therapies for the treatment of RCC have largely been focused on blocking angiogenesis. Sunitinib, an antiangiogenic tyrosine kinase inhibitor, is the most frequently used first-line drug for the treatment of RCC. Although treatment with sunitinib improves patient outcome considerably, acquired resistance will emerge in all cases. The molecular mechanisms of resistance to sunitinib are poorly understood, but in the past decade, several of these have been proposed. Lysosomal sequestration of sunitinib was reported as a potential resistance mechanism to sunitinib. In this review, the underlying molecular mechanisms of lysosomal sunitinib sequestration and the potential strategies to overcome this resistance are discussed to be able to further improve the treatment of RCC.
Codon Publications
2016-01-21
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/44
10.15586/jkcvhl.2015.44
Journal of Kidney Cancer and VHL; Vol. 2 No. 4 (2015): Journal Of Kidney Cancer and VHL; 195-203
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/44/113
https://jkcvhl.com/index.php/jkcvhl/article/view/44/114
Copyright (c) 2016 Kaamar Azijli, Kristy J Gotink, Henk M.W Verheul
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/45
2021-10-22T05:59:23Z
jkcvhl:KCREV
Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies
Yip, Steven M.
Heng, Daniel Y.C.
Tang, Patricia A.
adiposity
body composition
obesity
renal cell carcinoma
sarcopenia
targeted therapy
toxicity
Treatment of metastatic renal cell cancer (mRCC) currently focuses on inhibition of the vascular endothelial growth factor pathway and the mammalian target of rapamycin (mTOR) pathway. Obesity confers a higher risk of RCC. However, the influence of obesity on clinical outcomes in mRCC in the era of targeted therapy is less clear. This review focuses on the impact of body composition on targeted therapy outcomes in mRCC. The International Metastatic Renal Cell Carcinoma Database Consortium database has the largest series of patients evaluating the impact of body mass index (BMI) on outcomes in mRCC patients treated with targeted therapy. Overall survival was significantly improved in overweight patients (BMI ≥ 25 kg/m2), and this observation was externally validated in patients who participated in Pfizer trials. In contrast, sarcopenia is consistently associated with increased toxicity to inhibitors of angiogenesis and mTOR. Strengthening patients with mRCC and sarcopenia, through a structured exercise program and dietary intervention, may improve outcomes in mRCC treated with targeted therapies. At the same time, the paradox of obesity being a risk factor for RCC while offering a better overall survival in response to targeted therapy needs to be further evaluated.
Codon Publications
2016-03-22
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/45
10.15586/jkcvhl.2016.45
Journal of Kidney Cancer and VHL; Vol. 3 No. 1 (2016): Journal Of Kidney Cancer and VHL; 12-22
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/45/120
https://jkcvhl.com/index.php/jkcvhl/article/view/45/121
Copyright (c) 2016 Steven M Yip, Daniel Y. C. Heng, Patricia A. Tang
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/46
2021-10-22T09:08:27Z
jkcvhl:KCREV
Sequential Therapy in Metastatic Renal Cell Carcinoma
Hirsch, Bradford R.
Burke, John M.
Agrawal, Manish
Hauke, Ralph J.
Hutson, Thomas E.
Doshi, Gury
Fleming, Mark T.
Vogelzang, Nicholas J.
kidney cancer
renal cell carcinoma
sequential therapy
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The authors are practicing medical oncologists at the US Oncology Network, the largest community-based network of oncology providers in the country, and represent the leadership of the Network's Genitourinary Research Committee. We outline our thought process in approaching sequential therapy of mRCC and the use of real-world data to inform our approach. We also highlight the evolving literature that will impact practicing oncologists in the near future.
Codon Publications
2016-04-05
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/46
10.15586/jkcvhl.2016.46
Journal of Kidney Cancer and VHL; Vol. 3 No. 1 (2016): Journal Of Kidney Cancer and VHL; 23-35
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/46/123
https://jkcvhl.com/index.php/jkcvhl/article/view/46/124
Copyright (c) 2016 Bradford R Hirsch, John M Burke, Manish Agrawal, Ralph J Hauke, Thomas E Hutson, Gury Doshi, Mark T Fleming, Nicholas J Vogelzang
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/47
2021-10-22T09:34:51Z
jkcvhl:KCART
Decreased Expression of Inhibitor of Caspase-Activated DNase (ICAD) in Renal Cell Carcinoma –Tissue Microarray of Human Samples
Rajandram, Retnagowri
Razack, Azad H. A.
Ng, Keng Lim
Gobe, Glenda C.
apoptosis
ICAD
kidney cancer
renal cell carcinoma
tissue microarray
Kidney Cancer
Pathology
Oncology
Although primary localised tumours of renal cell carcinoma (RCC) can be treated relatively successfully with surgery, metastatic RCC has poor prognosis because of late diagnosis and resistance to therapies. In the present study, we were interested in profiling the protein expression of “inhibitor of caspase-activated DNase” (ICAD), an apoptosis inhibitor, in kidney cancer and its paired normal kidney. Immunohistochemistry with automated batch staining and morphometry using digital pathology were used to compare ICAD in 121 RCC specimens with their paired normal kidney tissue. Tissue microarray of formalin-fixed, paraffin-embedded archival tissue was used. Intensity and localisation of ICAD were compared between normal and cancer samples, and against grading within the cancers. The results demonstrated that, in this cohort, ICAD was highly expressed in the proximal tubular epithelium of normal kidney, and significantly decreased in clear cell RCC tissue (p < 0.05) as well as other subtypes of RCC (p < 0.01) compared with normal kidney. There was a tendency towards nuclear localisation of ICAD in clear cell RCC, but not in other subtypes of RCC. No significant association was found between ICAD intensity and grade of RCC. In summary, down-regulation of ICAD occurs in RCC. ICAD normally inhibits DNA fragmentation and apoptosis; thus, its down-regulation was unexpected in a cancer known for its resistance to apoptosis. However, these RCC samples were from primary, not metastatic, RCC sites, and down-regulated ICAD may be part of a progressive pathway that promotes RCC metastasis.
Codon Publications
2016-03-22
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/47
10.15586/jkcvhl.2016.47
Journal of Kidney Cancer and VHL; Vol. 3 No. 1 (2016): Journal Of Kidney Cancer and VHL; 1-11
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/47/118
https://jkcvhl.com/index.php/jkcvhl/article/view/47/116
Copyright (c) 2016 Glenda C Gobe, MSc, PhD
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/51
2021-10-21T12:03:47Z
jkcvhl:KCCR
Unusual Case of Coexisting Renal Malignancies: Mucinous Tubular and Spindle Cell Carcinoma Kidney With Sarcomatoid Dedifferentiation
Akhtar, Kafil
Agnihotri, Pragati
Alam, Kiran
Raza, Kashif
immunohistochemistry
kidney
mucinous
sarcomatoid dedifferentiation
spindle cell carcinoma
Mucinous tubular and spindle cell carcinoma (MTSCC) is a recent entity introduced in the World Health Organization 2004 Classification. It is a tumour of low malignant potential. MTSCC is a subtype of renal cell carcinoma (RCC), which is characterized by a polymorphous histology, wherein the spindled epithelial cell is an inherent carcinomatous component. We report the case of a 57-year-old man presenting with loin pain and dragging sensation. Imaging revealed a large mass arising from the left kidney. Radical nephrectomy was performed, and histopathology revealed spindle cell elements of MTSCC with low-grade cytology, which occasionally blended with tubular structures in variable mucinous stroma admixed with spindle sarcomatoid cells with marked nuclear pleomorphism, associated with significant necrosis and mitoses of up to 5/10 high-power field. A final diagnosis of MTSCC along with high-grade areas consistent with sarcomatoid dedifferentiation was made. Sarcomatoid dedifferentiation has been well documented in various subtypes of RCC, and its presence signifies a worse prognosis in RCC.
Codon Publications
2016-05-31
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/51
10.15586/jkcvhl.2016.51
Journal of Kidney Cancer and VHL; Vol. 3 No. 2 (2016): Journal of Kidney Cancer and VHL; 8-13
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/51/133
https://jkcvhl.com/index.php/jkcvhl/article/view/51/134
Copyright (c) 2016 KAFIL AKHTAR, PRAGATI AGNIHOTRI, KIRAN ALAM, KASHIF RAZA
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/52
2021-10-20T10:34:49Z
jkcvhl:KCCR
Adult Wilms' Tumour: Case Report and Review of Literature
Modi, Sunny
Woi Tiang, Kor
Inglis, Po
Collins, Stuart
adult Wilms’ tumour
nephroblastoma
renal tumour
Kidney Cancer
Wilms' tumour (nephroblastoma) is the most common renal tumour in children. Wilms' tumour in adults is extremely rare and has a poorer prognosis than paediatric Wilms' tumour. It is difficult to differentiate adult Wilms' tumour from renal cell carcinoma based on radiological findings alone. The diagnosis in adults is often serendipitous following nephrectomy for presumed renal cell carcinoma. Because of the paucity of literature, there are no standard protocols for the management of adult Wilms' tumour, and therefore, it is managed as per paediatric Wilms' tumour. Herein, we report the case of adult Wilms' tumour in a 43-year-old man, which was diagnosed unexpectedly following nephrectomy for presumed renal cell carcinoma.
Codon Publications
2016-05-23
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/52
10.15586/jkcvhl.2016.52
Journal of Kidney Cancer and VHL; Vol. 3 No. 2 (2016): Journal of Kidney Cancer and VHL; 1-7
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/52/130
https://jkcvhl.com/index.php/jkcvhl/article/view/52/131
Copyright (c) 2016 Sunny Modi, Kor Woi, Stuart Collins
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/53
2021-10-21T13:29:08Z
jkcvhl:KCCR
Multifocal Primary Neoplasms in Kidney Allografts: Evaluation of Two Cases
Ellis, Robert J.
Ng, Keng Lim
Samaratunga, Hemamali
Vecchio, Sharon J. Del
Wood, Simon T.
Gobe, Glenda C
multifocal
renal allograft
renal cell carcinoma
renal neoplasm
Kidney cancer
oncology
Renal cell carcinoma (RCC) is the fifth most common malignancy in kidney transplant recipients, with increased risk arising due to immunosuppression. De novo RCC occurrence in kidney allografts is much less common when compared with the native kidneys. Multifocal RCC in allograft kidneys is rarely described. In this report, we discuss two cases of de novo multifocal renal neoplasms in allograft kidneys. Case 1 had three distinct neoplastic lesions of >5 mm, and case 2 had four. Using the World Health Organization 2016 classification of adult renal tumours, case 1 had one clear-cell (cc) RCC (grade 3) and two papillary adenomas; all confined to the kidney. Case 2 had a nodular lesion classified as ccRCC (grade 4) with focal rhabdoid differentiation and some infiltration of renal sinus fat; a cc tubulopapillary RCC; a multilocular cystic renal neoplasm of low malignant potential; and a mucinous tubular and spindle cell carcinoma; the last three all confined to the kidney. This is the first report of mucinous tubular and spindle cell carcinoma in a kidney allograft. When considering multifocal RCC with discordant histology, it is likely that these represent independent tumourigenic events.
Codon Publications
2016-06-13
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/53
10.15586/jkcvhl.2016.53
Journal of Kidney Cancer and VHL; Vol. 3 No. 2 (2016): Journal of Kidney Cancer and VHL; 14-22
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/53/135
https://jkcvhl.com/index.php/jkcvhl/article/view/53/136
Copyright (c) 2016 Robert J Ellis, Keng Lim Ng, Hemamali Samaratunga, Sharon J Del Vecchio, Simon T Wood, Glenda C Gobe
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/56
2021-10-18T10:49:06Z
jkcvhl:KCREV
The Emerging Role of Histone Demethylases in Renal Cell Carcinoma
Guo, Xiaoqiang
Zhang, Qiaoxia
histone demethylases
KDM3A
KDM5C
KDM6A
KDM6B
renal cell carcinoma
Renal cell carcinoma (RCC), the most common kidney cancer, is responsible for more than 100,000 deaths per year worldwide. The molecular mechanism of RCC is poorly understood. Many studies have indicated that epigenetic changes such as DNA methylation, noncoding RNAs, and histone modifications are central to the pathogenesis of cancer. Histone demethylases (KDMs) play a central role in histone modifications. There is emerging evidence that KDMs such as KDM3A, KDM5C, KDM6A, and KDM6B play important roles in RCC. The available literature suggests that KDMs could promote RCC development and progression via hypoxia-mediated angiogenesis pathways. Small-molecule inhibitors of KDMs are being developed and used in preclinical studies; however, their clinical relevance is yet to be established. In this mini review, we summarize our current knowledge on the putative role of histone demethylases in RCC.
Codon Publications
2017-05-03
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/56
10.15586/jkcvhl.2017.56
Journal of Kidney Cancer and VHL; Vol. 4 No. 2 (2017): Journal of Kidney Cancer and VHL; 1-5
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/56/150
https://jkcvhl.com/index.php/jkcvhl/article/view/56/154
https://jkcvhl.com/index.php/jkcvhl/article/view/56/169
Copyright (c) 2017 Xiaoqiang Guo, Qiaoxia Zhang
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/58
2021-10-20T10:19:01Z
jkcvhl:KCART
Rat Kidney Cancers Determined by Dietary Ochratoxin A in the First Year of Life
Mantle, Peter
Balkan endemic nephropathy
karyomegaly
latency
leukaemia
renal cell carcinoma
urothelial cancer
Kidney cancer
An experiment to explore renal carcinogenic efficacy of male rat exposure to dietary ochratoxin A (OTA) only in the first year of life has been made in comparison to lifetime exposure. Ten months exposure to OTA at 300 μg/kg b.w. was sufficient to cause high incidence of tumours which became apparent clinically after a latency of up to a year. As a putative model for human kidney cancer, the study shows a silent organ-specific carcinogenic effect through protracted exposure up to middle age and focused probably on very few nephrons. So far, tumourigenesis has not been recognised until in the last quarter of natural rat life, but for OTA, rat renal carcinogenesis requires both long exposure and only during the first year of normal longevity. The present findings offer an experimental framework within which systematic histopathology during tumourigenesis might show whether findings of mechanistic studies in key focal neoplasms can reasonably be applied to OTA as a putative renal carcinogen for idiopathic kidney cancer in humans. Already, the rat tumours mimic those occurring spontaneously in the Eker rat, and there is disparity between the large necessary OTA exposure in the rat and the trace amounts of OTA consumed by humans. In all such complex considerations it is important to adhere rigorously to established principles of disease epidemiology.
Codon Publications
2016-09-26
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/pdf
https://jkcvhl.com/index.php/jkcvhl/article/view/58
10.15586/jkcvhl.2016.58
Journal of Kidney Cancer and VHL; Vol. 3 No. 3 (2016): Journal of Kidney Cancer and VHL; 1-10
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/58/138
https://jkcvhl.com/index.php/jkcvhl/article/view/58/137
https://jkcvhl.com/index.php/jkcvhl/article/view/58/240
10.15586/jkcvhl.2016.58.61
Copyright (c) 2016 Peter George Mantle
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/59
2021-10-19T11:37:11Z
jkcvhl:KCART
Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis
Eggers, Hendrik
Ivanyi, Philipp
Hornig, Mareike
Grünwald, Viktor
clinical decision making
predictive markers
renal cell cancer
second-line therapy
targeted therapy
Currently, about 50% of patients with metastatic renal cell carcinoma (mRCC) receive a second-line therapy. Therefore, the choice at each subsequent treatment line remains an important issue. In this retrospective study, we sought to identify pretreatment clinical parameters that could predict the likelihood of a patient receiving a second-line therapy. One hundred and sixty-one mRCC patients who received targeted therapy were evaluated. Descriptive statistics, Kaplan–Meier overall survival (OS), Cox regression, and binary logistic regression models were used for data analysis. Second-line therapy was given to 105 patients (65%). Patients with grade 1 tumor received second-line therapy more frequently than those with grade 2/3 tumors (P = 0.03). Only tumor grade was significantly different between patients receiving, or not receiving, second-line treatment. Median OS was significantly superior in patients receiving second-line therapy (32 versus 14 months; P = 0.007; hazard ratio [HR], 1.75; P = 0.008), patients with grade 1 tumors (130 versus 29 months in G2/3 tumors; HR, 3.85; P = 0.009), and in patients without early tumor progression (41 versus 11 months; HR, 5.04; 95% confidence interval [CI], 3.06–8.31; P < 0.001). In binary logistic regression, we identified early progression to be significantly associated with a higher probability of not receiving a second-line therapy (HR, 2.50; 95% CI, 1.01–6.21; P = 0.048). This study hypothesizes that pretreatment grade and early progression are predictive parameters for the selection of patients for second-line therapy.
Codon Publications
2017-03-21
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/59
10.15586/jkcvhl.2017.59
Journal of Kidney Cancer and VHL; Vol. 4 No. 1 (2017): Journal of Kidney Cancer and VHL; 8-15
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/59/142
https://jkcvhl.com/index.php/jkcvhl/article/view/59/144
Copyright (c) 2017 Hendrik Eggers, Philipp Ivanyi, Mareike Hornig, Viktor Grünwald
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/61
2021-10-20T10:08:42Z
jkcvhl:KCCR
Unilateral Blepharoptosis from Renal Cell Carcinoma
Greco, Federico
Sabatino, Lorenzo
Sabatino, Francesco
Casale, Manuele
Quattrocchi, Carlo Cosimo
Beomonte Zobel, Bruno
blepharoptosis
kidney cancer
orbital MRI
ptosis
renal cell carcinoma
Blepharoptosis is the drooping or inferior displacement of the upper eyelid. Blepharoptosis can be either congenital or acquired. Tumour metastasis is one of the acquired causes of blepharop-tosis. The lungs, locoregional lymph nodes, bone and liver are the usual sites of metastases of renal cell carcinoma (RCC); however, unusual locations of RCC have also been reported. Herein, we describe a case of a 47-year-old man with unilateral ptosis and blurred vision due to meta-static RCC. We describe the different causes of blepharopstosis, the path that led to the diagno-sis, and how RCC can metastasize to unusual anatomical regions such as the orbit. Symptoms such as exophthalmos, lid edema, diplopia, ptosis, cranial nerve paralysis or blurred vision may mime a benign disease; however, they could also be the symptoms of a systemic malignancy.
Codon Publications
2016-12-23
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
https://jkcvhl.com/index.php/jkcvhl/article/view/61
10.15586/jkcvhl.2016.61
Journal of Kidney Cancer and VHL; Vol. 3 No. 3 (2016): Journal of Kidney Cancer and VHL; 11-15
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/61/139
https://jkcvhl.com/index.php/jkcvhl/article/view/61/141
Copyright (c) 2016 Federico Greco, Lorenzo Sabatino, Francesco Sabatino, Manuele Casale, Carlo Cosimo Quattrocchi, Bruno Beomonte Zobel
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/62
2021-10-19T10:45:47Z
jkcvhl:KCREV
Imaging of Renal Medullary Carcinoma
Greco, Federico
Faiella, Eliodoro
Santucci, Domiziana
Augusto Mallio, Carlo
Nezzo, Marco
Quattrocchi, Carlo Cosimo
Beomonte Zobel, Bruno
Grasso, Rosario Francesco
Computed tomography
contrast-enhanced ultrasound
magnetic resonance imaging
renal cell carcinoma
renal medullary carcinoma
Kidney Cancer
Diagnostic Imaging
Renal medullary carcinoma (RMC) is a rare, highly aggressive tumor recognized as an independent pathological entity. African-descent adolescents and young adults with sickle cell hemoglobinopathy are the most affected groups. This rare subtype of renal cell carcinoma has its own morphogenetic and pathological characteristics. The major clinical manifestations include gross hematuria, abdominal or flank pain, and weight loss. The prognosis is very poor, with 95% of cases diagnosed at an advanced stage of the disease. In this review, we summarize the morphologic and dynamic characteristics of RMC under various imaging modalities such as ultrasound, computed tomography, and magnetic resonance. Differential diagnosis and management strategies are also discussed.
Codon Publications
2017-03-21
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/62
10.15586/jkcvhl.2017.62
Journal of Kidney Cancer and VHL; Vol. 4 No. 1 (2017): Journal of Kidney Cancer and VHL; 1-7
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/62/145
https://jkcvhl.com/index.php/jkcvhl/article/view/62/147
Copyright (c) 2017 Federico Greco, Eliodoro Faiella, Domiziana Santucci, Carlo Augusto Mallio, Marco Nezzo, Carlo Cosimo Quattrocchi, Bruno Beomonte Zobel, Rosario Francesco Grasso
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/64
2021-10-19T12:12:31Z
jkcvhl:KCART
Maslinic Acid Inhibits Proliferation of Renal Cell Carcinoma Cell Lines and Suppresses Angiogenesis of Endothelial Cells
Thakor, Parth
Song, Wenzhe
Subramanian, Ramalingam B.
Thakkar, Vasudev R.
Vesey, David A.
Gobe, Glenda C.
angiogenesis
maslinic acid
proliferating cell nuclear antigen
renal cell carcinoma
vascular endothelial growth factor
Despite the introduction of many novel therapeutics in clinical practice, metastatic renal cell carcinoma (RCC) remains a treatment-resistant cancer. As red and processed meat are considered risk factors for RCC, and a vegetable-rich diet is thought to reduce this risk, research into plant-based therapeutics may provide valuable complementary or alternative therapeutics for the management of RCC. Herein, we present the antiproliferative and antiangiogenic effects of maslinic acid, which occurs naturally in edible plants, particularly in olive fruits, and also in a variety of medicinal plants. Human RCC cell lines (ACHN, Caki-1, and SN12K1), endothelial cells (human umbilical vein endothelial cell line [HUVEC]), and primary cultures of kidney proximal tubular epithelial cells (PTEC) were treated with maslinic acid. Maslinic acid was relatively less toxic to PTEC when compared with RCC under similar experimental conditions. In RCC cell lines, maslinic acid induced a significant reduction in proliferation, proliferating cell nuclear antigen, and colony formation. In HUVEC, maslinic acid induced a significant reduction in capillary tube formation in vitro and vascular endothelial growth factor. This study provides a rationale for incorporating a maslinic acid–rich diet either to reduce the risk of developing kidney cancer or as an adjunct to existing antiangiogenic therapy to improve efficacy.
Codon Publications
2017-03-21
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
https://jkcvhl.com/index.php/jkcvhl/article/view/64
10.15586/jkcvhl.2017.64
Journal of Kidney Cancer and VHL; Vol. 4 No. 1 (2017): Journal of Kidney Cancer and VHL; 16-24
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/64/149
https://jkcvhl.com/index.php/jkcvhl/article/view/64/148
Copyright (c) 2017 Parth Thakor, Glenda C Gobe
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/68
2021-10-18T09:44:19Z
jkcvhl:KCCR
A Rare Case of Solitary Kidney Metastasis Following Primary Laryngeal Squamous Cell Carcinoma
Del Vecchio, Sharon
Ellis, Robert
Gallagher, Kylie
Ng, Keng Lim
Ma, Li
Strutton, Geoffrey
Wood, Simon
laryngeal squamous cell carcinoma
PET-MRI
renal cell carcinoma
smoking
solitary kidney metastasis
Kidney Cancer
Laryngeal cancer is the 14th most common malignancy worldwide, and its common subtype squamous cell carcinoma (SCC) is highly associated with tobacco use and long-term alcohol consumption. The incidence of distant metastasis from a primary laryngeal cancer has been reported to be very low, between 6.5% and 8.5%, according to published tumour registry data. Distant metastases of laryngeal SCC most commonly involve the lung, liver, bone and mediastinum, seldom involving the kidney. Renal metastasis has been well established in many other cancers such as lymphoma, lung, breast and gastric carcinoma. This report discusses the rare case of a solitary renal metastasis following a primary laryngeal SCC.
Codon Publications
2017-05-03
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/68
10.15586/jkcvhl.2017.68
Journal of Kidney Cancer and VHL; Vol. 4 No. 2 (2017): Journal of Kidney Cancer and VHL; 6-9
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/68/157
https://jkcvhl.com/index.php/jkcvhl/article/view/68/158
https://jkcvhl.com/index.php/jkcvhl/article/view/68/173
Copyright (c) 2017 Sharon Juliet Del Vecchio, Robert Ellis, Simon Wood, Kylie Gallagher, Keng Lim Ng, Li Ma, Geoffrey Strutton
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/69
2021-10-18T12:17:38Z
jkcvhl:KCREV
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition
Barata, Pedro C.
Ornstein, Moshe C.
Garcia, Jorge A.
Advanced renal cell carcinoma
immunotherapy
mTOR inhibitors
PD-1/PD-L1
sequential therapy
VEGF inhibitors
Kidney Cancer
Oncology
Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs.
Codon Publications
2017-05-11
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/69
10.15586/jkcvhl.2017.69
Journal of Kidney Cancer and VHL; Vol. 4 No. 2 (2017): Journal of Kidney Cancer and VHL; 10-18
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/69/160
https://jkcvhl.com/index.php/jkcvhl/article/view/69/161
https://jkcvhl.com/index.php/jkcvhl/article/view/69/170
Copyright (c) 2017 pedro barata
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/70
2021-10-19T05:55:32Z
jkcvhl:KCREV
The Pathology and Molecular Genetics of Sarcomatoid Renal Cell Carcinoma: A Mini-Review
Wei, Shuanzeng
Al-Saleem, Tahseen
carcinosarcoma
pathology reporting
sarcomatoid renal cell carcinoma
TP53
VHL
Kidney Cancer
pathology
Sarcomatoid renal cell carcinoma is a highly aggressive tumor. It is not a distinct histologic entity as it can be found in any subtypes of renal cell carcinoma. Recent molecular and genetic evidence suggest that sarcomatoid component is transformed from a common progenitor of the associated renal cell carcinoma, and the TP53 gene plays a pivotal role in this process. The presence of sarcomatoid carcinoma indicates poor prognosis, which also correlates with the amount of the sarcomatoid component. Therefore, the presence and quantity of sarcomatoid component should be reflected in pathology reports. However, pathology reporting seems to vary among laboratories prompting the need for a unified reporting system. We propose a pathology reporting system similar to that of transformed follicular lymphoma that is consistent with the molecular pathogenesis to ensure uniform reporting.
Codon Publications
2017-05-22
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/70
10.15586/jkcvhl.2017.70
Journal of Kidney Cancer and VHL; Vol. 4 No. 2 (2017): Journal of Kidney Cancer and VHL; 19-23
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/70/163
https://jkcvhl.com/index.php/jkcvhl/article/view/70/164
https://jkcvhl.com/index.php/jkcvhl/article/view/70/171
Copyright (c) 2017 Shuanzeng Wei, Tahseen Al-Saleem
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/75
2021-10-19T06:16:17Z
jkcvhl:KCART
Delayed Intervention of Small Renal Masses on Active Surveillance
Gupta, Mohit
Blute, Jr., Michael L.
Su, Li-Ming
Crispen, Paul L.
active surveillance
delayed intervention
renal cell carcinoma
renal mass
small renal mass
Kidney Cancer
Oncology
Although surgical excision is the standard of therapy for small renal masses (SRMs), there is a growing recognition of active surveillance as an option in select patients who are poor surgical candidates or who have shorter life expectancy. A number of patients on expectant management, however, subsequently advance to definitive therapy. In this study, we systematically reviewed the literature and performed a pooled analysis of active surveillance series to evaluate the rate and indications for definitive treatment after initiating a period of active surveillance. Fourteen clinical series (1245 patients; 1364 lesions) met our selection criteria. Mean lesion size at presentation was 2.30 ± 0.40 cm with a mean follow-up of 33.6 ± 16.9 months. Collectively, 34.0% of patients underwent delayed intervention, which ranged in individual series from 3.6% to 70.3%. Of patients undergoing delayed intervention, the average time on active surveillance prior to definitive treatment was 27.8 ± 10.6 months. A pooled analysis revealed that 41.0% of patients underwent therapy secondary to tumor growth rate and 51.9% secondary to patient or physician preference in the absence of clinical progression. Overall, 1.1% of all patients progressed to metastatic disease during the average follow-up period. Thus, active surveillance may be an appropriate option for carefully selected patients with SRMs. However, delayed treatment is pursued in a significant percentage of patients within 3 years. Prospective registries and clinical trials with standardized indications for delayed intervention are needed to establish true rates of disease progressions and recommendations for delayed intervention.
Codon Publications
2017-05-24
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/75
10.15586/jkcvhl.2017.75
Journal of Kidney Cancer and VHL; Vol. 4 No. 2 (2017): Journal of Kidney Cancer and VHL; 24-30
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/75/166
https://jkcvhl.com/index.php/jkcvhl/article/view/75/167
https://jkcvhl.com/index.php/jkcvhl/article/view/75/172
Copyright (c) 2017 Mohit Gupta, Paul Crispen, Michael Blute, Jr, Li-Ming Su
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/79
2021-10-17T09:54:46Z
jkcvhl:KCREV
Ultrasound Imaging of Cystic Nephroma
Greco, Federico
Faiella, Eliodoro
Santucci, Domiziana
De Lisi, Delia
Lo Vullo, Gianguido
Beomonte Zobel, Bruno
Francesco Grasso, Rosario
cystic nephroma
cystic renal cell carcinoma
DICER1
mixed epithelial stromal tumor
renal cystic lesions
Kidney Cancer
Cystic Nephroma
Diagnostic Imaging
Cystic nephroma is a rare, benign multicystic lesion of the kidney. This tumor occurs both in children and in adults. In children, it is highly prevalent in males; in adults, it is more frequent in women. The term “cystic nephroma” represents two apparently different entities: pediatric cystic nephroma, a benign form thought to originate from metanephric tissue, and adult cystic nephroma, considered as a lesion of mixed epithelial stromal tumor. The clinical presentation may be a palpable mass or nonspecific symptoms such as abdominal pain, hematuria, and urinary tract infections. In this review, we summarize the ultrasound imaging features of cystic nephroma and describe the characteristics of the most common renal cystic lesions and the differential diagnosis of cystic nephroma with other renal cystic lesions.
Codon Publications
2017-07-20
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/79
10.15586/jkcvhl.2017.79
Journal of Kidney Cancer and VHL; Vol. 4 No. 3 (2017): Journal of Kidney Cancer and VHL; 1-9
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/79/175
https://jkcvhl.com/index.php/jkcvhl/article/view/79/176
https://jkcvhl.com/index.php/jkcvhl/article/view/79/177
Copyright (c) 2017 Federico Greco, Eliodoro Faiella, Domiziana Santucci, Delia De Lisi, Gianguido Lo Vullo, Bruno Beomonte Zobel, Rosario Francesco Grasso
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/82
2021-10-17T10:32:02Z
jkcvhl:KCART
Trends in the Management of Small Renal Masses: A Survey of Members of the Endourological Society
Mohapatra, Anand
M. Potretzke, Aaron
Weaver, John
G. Anderson, Barrett
Vetter, Joel
Figenshau, Robert S.
active surveillance
laparoscopic ablation
minimally invasive nephrectomy
robotic nephrectomy
small renal masses
Kidney Cancer
Oncology
Treatment modalities for small renal masses (SRMs) include open or minimally invasive radical or partial nephrectomy, and laparoscopic or percutaneous ablations. Members of the Endourological Society were surveyed to evaluate how practitioner and clinical practice characteristics may be associated with the management of SRMs over time. The survey assessed characteristics of urologists (recency of residency and fellowship training, clinical practice type and location, and treatment modalities available) and their management of SRMs over the past year and over the course of the year 5 years prior. Of the 1495 surveys e-mailed, there were 129 respondents (8.6%). Comparing the past year to 5 years prior, there was increasing utilization of robotic partial nephrectomy (p < 0.001) and robotic radial nephrectomy (p = 0.031). In contrast, there was decreasing utilization of open partial nephrectomy (p < 0.001), open radical nephrectomy (p = 0.039), laparoscopic partial nephrectomy (p = 0.002), and laparoscopic radical nephrectomy (p = 0.041). Employment of laparoscopic ablation decreased (p = 0.001), but that of percutaneous ablation did not change significantly. For masses treated with image-guided therapy, there was increasing utilization of microwave ablation (p = 0.008) and decreasing usage of radiofrequency ablation (p = 0.002). Future studies should focus on the most effective treatment modalities based on provider, patient, and tumor characteristics.
Codon Publications
2017-07-20
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
application/pdf
https://jkcvhl.com/index.php/jkcvhl/article/view/82
10.15586/jkcvhl.2017.82
Journal of Kidney Cancer and VHL; Vol. 4 No. 3 (2017): Journal of Kidney Cancer and VHL; 10-19
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/82/178
https://jkcvhl.com/index.php/jkcvhl/article/view/82/179
https://jkcvhl.com/index.php/jkcvhl/article/view/82/180
https://jkcvhl.com/index.php/jkcvhl/article/view/82/241
10.15586/jkcvhl.2017.82.98
Copyright (c) 2017 Anand Mohapatra, Aaron Potretzke, John Weaver, Barrett Anderson, Joel Vetter, Robert Figenshau
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/88
2021-10-18T08:57:32Z
jkcvhl:VHL
A Review of Von Hippel-Lindau Syndrome
Varshney, Neha
Kebede, Amanuel A.
Owusu-Dapaah, Harry
Lather, Jason
Kaushik, Manu
Bhullar, Jasneet S.
endolymphatic sac tumors
emangioblastomas
pancreatic neuroendocrine tumors
pheochromocytoma
von Hippel-Lindausyndrome
VHL
Von Hippel-Lindau syndrome (VHL) is a familial neoplastic condition seen in approximately 1 in 36,000 live births. It is caused by germline mutations of the tumor suppressor gene VHL, located on the short arm of chromosome 3. While the majority of the affected individuals have a positive family history, up to 20% of cases arise from de novo mutations. VHL syndrome is characterized by the presence of benign and malignant tumors affecting the central nervous system, kidneys, adrenals, pancreas, and reproductive organs. Common manifestations include hemangioblastomas of the brain, spinal cord, and retina; pheochromocytoma and paraganglioma; renal cell carcinoma; pancreatic cysts and neuroendocrine tumors; and endolymphatic sac tumors. Diagnosis of VHL is prompted by clinical suspicion and confirmed by molecular testing. Management of VHL patients is complex and multidisciplinary. Routine genetic testing and surveillance using various diagnostic techniques are used to help monitor disease progression and implement treatment options. Despite recent advances in clinical diagnosis and management, life expectancy for VHL patients remains low at 40–52 years. This article provides an overview of the major clinical, histological, and radiological findings, as well as treatment modalities.
Codon Publications
2017-08-02
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/88
10.15586/jkcvhl.2017.88
Journal of Kidney Cancer and VHL; Vol. 4 No. 3 (2017): Journal of Kidney Cancer and VHL; 20-29
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/88/181
https://jkcvhl.com/index.php/jkcvhl/article/view/88/182
https://jkcvhl.com/index.php/jkcvhl/article/view/88/183
Copyright (c) 2017 Neha Varshney MD, Amanuel A Kebede MD, Harry Owusu-Dapaah MD, Jason Lather MD, Manu Kaushik MD, Jasneet Singh Bhullar MD, MS
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/90
2021-10-18T07:50:49Z
jkcvhl:HEM
Management Strategies and Outcomes for VHL-related Craniospinal Hemangioblastomas
Ordookhanian, Christ
Kaloostian, Paul E.
Ghostine, Samer S.
Spiess, Philippe E.
Etame, Arnold B.
craniospinal hemangioblastoma
natural history
radiographic diagnosis
surgical resection
von Hippel–Lindau syndrome
Oncology
Hemangioblastomas are rare and benign tumors accounting for less than 2% of all central nervous system (CNS) tumors. The vast majority of hemangioblastomas occur sporadically, whereas a small number of cases, especially in younger patients, are associated with Von Hippel–Lindau (VHL) syndrome. It is thought that loss of tumor suppressor function of the VHL gene results in stabilization of hypoxia-inducible factor alpha with downstream activation of cellular proliferative and angiogenic genes that promote tumorigenesis. VHL-related hemangioblastomas predominantly occur in the cerebellum and spine. Lesions are often diagnosed on contrast-enhanced craniospinal MRIs, and the diagnosis of VHL occurs through assessment for germline VHL mutations. Surgical resection remains the primary treatment modality for symptomatic or worrisome lesions, with excellent local control rates and neurological outcomes. Stereotactic radiotherapy can be employed in patients who are deemed high risk for surgery, have multiple lesions, or have non-resectable lesions. Given the tendency for development of either new or multiple lesions, close radiographic surveillance is often recommended for asymptomatic lesions.
Codon Publications
2017-08-28
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/90
10.15586/jkcvhl.2017.90
Journal of Kidney Cancer and VHL; Vol. 4 No. 3 (2017): Journal of Kidney Cancer and VHL; 37-44
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/90/184
https://jkcvhl.com/index.php/jkcvhl/article/view/90/185
https://jkcvhl.com/index.php/jkcvhl/article/view/90/186
Copyright (c) 2017 Christ Ordookhanian, Paul E Kaloostian, Samer S Ghostine, Philippe E Spiess, Arnold B Etame
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/92
2021-10-18T09:23:31Z
jkcvhl:VHL
Functional Imaging of Paragangliomas with an Emphasis on Von Hippel–Lindau-Associated Disease: A Mini Review
Ilias, Ioannis
Meristoudis, Georgios
imaging
paraganglioma
pheochromocytoma
radionuclide
von-Hippel-Lindau
Oncology
Few reports have presented data and results on functional (i.e., nuclear medicine) imaging of paragangliomas and pheochromocytomas (PGLs/PHEOs) for von Hippel–Lindau (VHL) patients. Nuclear medicine localization modalities for chromaffin tumors can be specific or nonspecific. Specific methods make use of the expression of the human norepinephrine transporter (hNET) and vesicular monoamine transporters (VMATs) by these tumors. These permit the use of radiolabeled ligands that enter the synthesis and storage pathway of catecholamines. Nonspecific methods are not related to the synthesis, uptake, or storage of catecholamines but make use of the tumors’ high glucose metabolism or expression of somatostatin receptors. Consensuses and guidelines suggest that metastatic and sporadic PHEOs/PGLs in VHL patients (as in patients with chromaffin tumors of yet unknown genotype) should be evaluated first with 18F-dihydroxyphenylalanine (18F-DOPA) positron emission tomography/computed tomography (PET/CT). The functional imaging of second choice is 123I-metaiodobenzylguanidine (123I-MIBG) for PHEOs in VHL patients. 123I-MIBG, 68Ga-DOTATATE/DOTATOC/DOTANOC PET/CT, or 18F-fluorodeoxyglucose (18F-FDG) PET/CT can be a second choice of functional imaging for PGLs in VHL patients.
Codon Publications
2017-09-04
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/92
10.15586/jkcvhl.2017.92
Journal of Kidney Cancer and VHL; Vol. 4 No. 3 (2017): Journal of Kidney Cancer and VHL; 30-36
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/92/187
https://jkcvhl.com/index.php/jkcvhl/article/view/92/188
https://jkcvhl.com/index.php/jkcvhl/article/view/92/189
Copyright (c) 2017 Ioannis Ilias, Georgios Meristoudis
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/96
2021-10-15T06:40:29Z
jkcvhl:KCREV
Modern Pathologic Diagnosis of Renal Oncocytoma
Wobker, Sara E.
Williamson, Sean R.
chromophobe renal cell carcinoma
kidney
oncocytic neoplasm
oncocytoma
renal mass
renal mass biopsy
succinate dehydrogenase-deficient renal cell carcinoma
Oncocytoma is a well-defined benign renal tumor, with classic gross and histologic features, including a tan or mahogany-colored mass with central scar, microscopic nested architecture, bland cytology, and round, regular nuclei with prominent central nucleoli. As a result of variations in this classic appearance, difficulty in standardizing diagnostic criteria, and entities that mimic oncocytoma, such as eosinophilic variant chromophobe renal cell carcinoma and succinate dehydrogenase-deficient renal cell carcinoma, pathologic diagnosis remains a challenge. This review addresses the current state of pathologic diagnosis of oncocytoma, with emphasis on modern diagnostic markers, areas of controversy, and emerging techniques for less invasive diagnosis, including renal mass biopsy and advanced imaging.
Codon Publications
2017-10-09
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/96
10.15586/jkcvhl.2017.96
Journal of Kidney Cancer and VHL; Vol. 4 No. 4 (2017): Journal of Kidney Cancer and VHL; 1-12
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/96/190
https://jkcvhl.com/index.php/jkcvhl/article/view/96/191
https://jkcvhl.com/index.php/jkcvhl/article/view/96/192
Copyright (c) 2017 Sara E Wobker, Sean R Williamson
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/97
2021-10-15T12:26:21Z
jkcvhl:KCREV
The Risks of Renal Angiomyolipoma: Reviewing the Evidence
Seyam, Raouf M.
Alkhudair, Waleed K.
Kattan, Said A.
Alotaibi, Mohamed F.
M. Alzahrani, Hassan
M. Altaweel, Waleed
angiomyolipoma
embolization
hemorrhage
kidney
nephrectomy
Renal angiomyolipoma (RAML), though a rare benign tumor, may impose a significant morbidity or even mortality due to its unique characteristics and the complications subsequent to its treatment. The classic tumor variant is composed of smooth muscular, vascular, and fatty components. The most straightforward diagnosis is when the fat component is abundant and gives a characteristic appearance on different imaging studies. In fat-poor lesions, however, the diagnosis is difficult and presumed a renal cell carcinoma. Yet, some variants of RAML, though rare, express an aggressive behavior leading to metastasis and mortality. The challenge lies in the early detection of benign variants and identifying aggressive lesions for proper management. Another challenge is when the vascular tissue component predominates and poses a risk of hemorrhage that may extend to the retroperitoneum in a massive life-threatening condition. The predicament here is to identify the characteristics of tumors at risk of bleeding and provide a prophylactic treatment. According to the clinical presentation, different treatment modalities, prophylactic or therapeutic, are available that span the spectrum of observation, embolization, or surgery. Renal impairment may result from extensive tumor burden or as a complication of the management itself. Improvement of diagnostic techniques, super-selective embolization, nephron-sparing surgery, and late treatment with the mammalian target of rapamycin inhibitors have provided more effective and safe management strategies. In this review, we examine the evidence pertaining to the risks imposed by RAML to the patients and identify merits and hazards associated with different treatment modalities.
Codon Publications
2017-10-16
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
application/pdf
https://jkcvhl.com/index.php/jkcvhl/article/view/97
10.15586/jkcvhl.2017.97
Journal of Kidney Cancer and VHL; Vol. 4 No. 4 (2017): Journal of Kidney Cancer and VHL; 13-25
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/97/193
https://jkcvhl.com/index.php/jkcvhl/article/view/97/196
https://jkcvhl.com/index.php/jkcvhl/article/view/97/197
https://jkcvhl.com/index.php/jkcvhl/article/view/97/242
10.15586/jkcvhl.2017.97.133
Copyright (c) 2017 Raouf Seyam, Waleed AlKhudair, Said Kattan, Mohamed Alotaibi, Hasan Alzahrani, Waleed Altaweel
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/99
2021-10-14T11:59:19Z
jkcvhl:KCCR
Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by 18F-FDG PET/CT: a Case Report and Review of Literature
Fuser, Dominique
Hedberg, Matthew L.
Dehner, Louis P.
Dehdashti, Farrokh
Siegel, Barry A.
FDG PET/CT
metastasis
PET/CT
renal cell carcinoma
sarcomatoid
Sarcomatoid renal cell carcinoma (sRCC) is a highly aggressive form of dedifferentiated renal cell carcinoma. We report a 62-year-old man who presented with respiratory symptoms and a lung mass on chest computed tomography (CT). The patient underwent positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) and was found to have extensive metastatic disease. Based on the history and imaging findings, there were possible primary malignancies, including bronchogenic carcinoma, melanoma, or an aggressive lymphoma. An excisional biopsy surprisingly revealed a high-grade sarcomatoid carcinoma with no evidence of differentiation, and immunohistochemical (IHC) studies showed that the tumor cells were positive for markers of genitourinary origin (PAX-8 and vimentin). The histologic and IHC results, along with multiple FDG-avid exophytic lesions in both kidneys, were considered diagnostic of sRCC. Here we have highlighted the potential role of 18F-FDG-PET-CT in patients with sRCC, discussed the diagnostic challenges, and presented a brief review.
Codon Publications
2018-01-12
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
application/pdf
https://jkcvhl.com/index.php/jkcvhl/article/view/99
10.15586/jkcvhl.2018.99
Journal of Kidney Cancer and VHL; Vol. 5 No. 1 (2018): Journal of Kidney Cancer and VHL; 1-6
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/99/198
https://jkcvhl.com/index.php/jkcvhl/article/view/99/199
https://jkcvhl.com/index.php/jkcvhl/article/view/99/200
https://jkcvhl.com/index.php/jkcvhl/article/view/99/243
10.15586/jkcvhl.2018.99.156
Copyright (c) 2018 Dominique Fuser, Matthew L. Hedberg, Louis P. Dehner, Farrokh Dehdashti, Barry A. Siegel
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/100
2021-10-15T04:43:58Z
jkcvhl:KCREV
Contrast-Enhanced Ultrasound-Guided Radiofrequency Ablation of Renal Tumo
O’Neal, Dan
Cohen, Tal
Peterson, Cynthia
G. Barr, Richard
contrast-enhanced ultrasound
radiofrequency ablation
renal tumor ablation
small renal masses
ultrasound contrast agents
Kidney Cancer
Treatment
Although only limited long-term studies evaluating thermal ablation of renal masses have been performed, it appears that thermal ablation has a comparable 5-year success rate to that of partial or total nephrectomy. This technique is often used in patients who are not good candidates for partial or total nephrectomy. Contrast-enhanced ultrasound (CEUS) has been recently approved by the Food and Drug Administration for characterization of focal liver lesions in adults and pediatric patients. CEUS can be used off label for renal applications and has been used for years in Europe and Asia. It has several advantages over contrast-enhanced computed tomography for use as the technique to guide and evaluate efficacy of thermal ablation of renal masses. These include the ability to visualize small amounts of enhancement, repeat dosing to evaluate efficacy of an ablation during a procedure, thin slice thickness, and real-time visualization. Ultrasound contrast is also non-nephrotoxic and non-hepatotoxic, allowing evaluation of patients with renal insufficiency. This article reviews the use of CEUS for the guidance and follow-up of thermal ablative procedures of renal masses.
Codon Publications
2018-02-02
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/100
10.15586/jkcvhl.2018.100
Journal of Kidney Cancer and VHL; Vol. 5 No. 1 (2018): Journal of Kidney Cancer and VHL; 7-14
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/100/201
https://jkcvhl.com/index.php/jkcvhl/article/view/100/202
https://jkcvhl.com/index.php/jkcvhl/article/view/100/203
Copyright (c) 2018 Richard G Barr, Daniel O'Neal, Tal Cohen, Cynthia Peterson
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/101
2021-10-15T05:22:07Z
jkcvhl:KCART
Checkpoint Kinase 2 (CHEK2) Mutation in Renal Cell Carcinoma: A Single-Center Experience
Huszno, Joanna
Kołosza, Zofia
checkpoint kinase 2 mutation
CHEK2 mutation
renal cell carcinoma
retrospective study
second neoplasm
Kidney cancer
oncology
genetics
Renal cell carcinoma (RCC) occurs in sporadic and heritable forms. Genetic mutations have been identified as risk factors in 1–2% of RCC. The aim of this study was to evaluate I157T and CHEK2*1100delC mutations of checkpoint kinase 2 (CHEK2) gene in RCC. Medical records of 40 clear cell RCC patients who had genetic tests and consultation at the Genetic Outpatient Clinic, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, were reviewed retrospectively. Mutation profile was assessed by ASA-PCR and RFLP-PCR techniques. Only three female patients had CHEK2 mutation (I157T). No CHEK2*1100delC was observed in any of the patients. These tumors were N0, and two were Grade 3. One showed capsular infiltration. No blood vessel infiltration or metastases was observed. Overall, RCC from patients with CHEK2 mutation did not display any special characteristics when compared with those without the mutation. While no association between CHEK2 mutation and RCC could be established, all three patients with CHEK2 mutation developed second neoplasms many years after first diagnosis. Further studies, especially regarding CHEK2 mutation as a predictive factor for second neoplasm in RCC patients, are warranted.
Codon Publications
2018-04-18
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/101
10.15586/jkcvhl.2018.101
Journal of Kidney Cancer and VHL; Vol. 5 No. 1 (2018): Journal of Kidney Cancer and VHL; 19-23
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/101/207
https://jkcvhl.com/index.php/jkcvhl/article/view/101/208
https://jkcvhl.com/index.php/jkcvhl/article/view/101/209
Copyright (c) 2018 Joanna Huszno
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/102
2021-10-15T04:58:58Z
jkcvhl:KCREV
Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives
Ochoa, Cesar E.
Joseph, Richard W.
checkpoint inhibitors
immunotherapy
nivolumab
renal cell carcinoma
targeted therapy
Kidney Cancer
Oncology
Targeted agents form the backbone of most therapeutic strategies in advanced renal cell carcinoma (aRCC) but ultimately resistance develops and toxicity often leads to discontinuation of treatment, limiting the clinical benefits of these treatments. Nivolumab, a fully human IgG4 anti-PD-1 antibody, selectively blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2 and provides a novel therapy option for patients with aRCC. In 2015, the pivotal phase III study CheckMate 025 led to the Food and Drug Administration approval of nivolumab in patients with aRCC who had received prior anti-angiogenic therapy, and in 2017, the phase III study CheckMate 214 showed that combined immunotherapy with nivolumab plus ipilimumab resulted in greater objective response rate and prolonged progression-free survival when compared with sunitinib in intermediate- and poor-risk patients with previously untreated aRCC. Early studies of nivolumab in association with anti-angiogenic therapy have generated enthusiasm and multiple combination trials are ongoing.
Codon Publications
2018-02-06
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/102
10.15586/jkcvhl.2018.102
Journal of Kidney Cancer and VHL; Vol. 5 No. 1 (2018): Journal of Kidney Cancer and VHL; 15-18
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/102/204
https://jkcvhl.com/index.php/jkcvhl/article/view/102/205
https://jkcvhl.com/index.php/jkcvhl/article/view/102/206
Copyright (c) 2018 Cesar E Ochoa, Richard W Joseph
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/104
2021-10-14T11:06:08Z
jkcvhl:VHL
VHL-Associated Optic Nerve Hemangioblastoma Treated with Stereotactic Radiosurgery
Kanno, Hiroshi
Osano, Seiki
Shinonaga, Masamichi
optic nerve hemangioblastoma
stereotactic radiosurgery
VHL
von Hippel-Lindau disease
Hemangioblastoma
Familial Cancer Syndrome
Central nervous system hemangioblastomas are generally restricted to the cerebellum, spinal cord, and brainstem. Supratentorial hemangioblastomas are uncommon, and optic nerve hemangioblastomas are extremely rare, with fewer than 25 reports including this case. In this report, we present the case of a 36-year-old woman with von Hippel–Lindau (VHL) disease who presented with progressive diminution of vision in the left eye due to a retrobulbar optic nerve hemangioblastoma. The patient had a history of cerebellar/spinal hemangioblastomas and pancreatic cysts, and her father and brother were patients with VHL disease. Gadol-inium-enhanced magnetic resonance imaging showed intraorbital retrobulbar–enhanced mass on the left optic nerve. The optic nerve hemangioblastoma was treated with fractionated stereotactic radiosurgery using Novalis. Eighteen months after the stereotactic radiosurgery, the tumor volume decreased although the patient lost vision. This report presents an extremely rare case of optic nerve hemangioblastoma, which is the first case treated with stereotactic radiosurgery.
Codon Publications
2018-06-06
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/104
10.15586/jkcvhl.2018.104
Journal of Kidney Cancer and VHL; Vol. 5 No. 2 (2018): Journal of Kidney Cancer and VHL; 1-6
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/104/212
https://jkcvhl.com/index.php/jkcvhl/article/view/104/211
https://jkcvhl.com/index.php/jkcvhl/article/view/104/213
Copyright (c) 2018 Hiroshi Kanno
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/106
2020-06-03T15:14:01Z
jkcvhl:KCART
oai:ojs.pkp.sfu.ca:article/107
2021-10-11T12:12:13Z
jkcvhl:KCART
Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma
Chipollini, Juan
Azizi, Mounsif
Peyton, Charles C.
Tang, Dominic H.
Dhillon, Jasreman
Spiess, Philippe E.
Non-Clear Cell Renal Cell Carcinoma
Prognosis
Programmed Death Ligand-1
renal cell cancer
tumor marker
Kidney Cancer
Oncology
The purpose of this study was to assess the prognostic value of programmed death ligand-1 (PD-L1) positivity in a non-clear cell renal cell carcinoma (non-ccRCC) cohort. PD-L1 expression was evaluated by immunohistochemistry (IHC) using formalin-fixed paraffin-embedded (FFPE) specimens from 45 non-ccRCC patients with available tissue. PD-L1 positivity was defined as ≥1% of staining. Histopathological characteristics and oncological outcomes were correlated to PD-L1 expression. Cancer-specific survival (CSS) and recurrence-free survival (RFS) stratified by PD-L1 status were estimated using the Kaplan–Meier method. Median age was 58 years and median follow-up was 40 months. Non-ccRCC subtypes included sarcomatoid (n = 9), rhabdoid (n = 6), medullary (n = 2), Xp11.2 translocation (n = 2), collecting duct (n = 1), papillary type I (n = 11), and papillary type II (n = 14). PD-L1 positivity was noted in nine (20%) patients. PD-L1 positivity was significantly associated with higher Fuhrman nuclear grade (P = 0.048) and perineural invasion (P = 0.043). Five-year CSS was 73.2 and 83% for PD-L1 positive and negative tumors, respectively (P = 0.47). Five-year RFS was 55.6 and 61.5% for PD-L1 positive and negative tumors, respectively (P = 0.58). PD-L1 was expressed in a fifth of non-ccRCC cases and was associated with adverse histopathologic features. Expression of biomarkers such PD-L1 may help better risk-stratify non-ccRCC patients to guide treatment decisions and follow-up strategies.
Codon Publications
2018-10-13
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/107
10.15586/jkcvhl.2018.107
Journal of Kidney Cancer and VHL; Vol. 5 No. 4 (2018): Journal of Kidney Cancer and VHL; 6-13
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/107/221
https://jkcvhl.com/index.php/jkcvhl/article/view/107/222
https://jkcvhl.com/index.php/jkcvhl/article/view/107/223
Copyright (c) 2018 Mounsif Azizi
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/108
2020-07-13T18:01:28Z
jkcvhl:KCART
Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
Kamli, Hossam
Gobe, Glenda C
Li, Li
Vesey, David A
Morais, Christudas
angiogenesis
anti-apoptosis
interleukin-6
renal cell carcinoma
sunitinib resistance
Kidney Cancer
Sunitinib resistance is a major clinical problem hampering the treatment of renal cell carcinoma (RCC). Studies on the comprehensive characterisation of morphological, functional and molecular changes in sunitinib-resistant RCC cells are lacking. The aim of the current study was to develop sunitinib resistance in four human RCC cell lines (786-0, Caki-1, Caki-2 and SN12K1), and to characterise the changed cell biology with sunitinib resistance. RCC cells were made resistant by continuous, chronic exposure to 10 µM of sunitinib over a period of 12 months. Cell proliferation, morphology, transmigration, and gene expression for interleukin-6 (IL-6), interleukin-8 (IL-8), vascular endothelial growth factor (VEGF), Bcl-2 and Bax were studied. There was no significant difference in growth rate or transmigration between the parental and resistant cells. Sunitinib-resistant cells were significantly hypertrophic compared with parental cells as evidenced by increases in the surface areas of the whole cells and the nuclei. IL-6 was significantly increased in all resistant cells. IL-8 was increased in sunitinib-resistant Caki-2 and SN12K1 cells and decreased in 786-0 without any significant changes in Caki-1. VEGF was increased in resistant Caki-2 and SN12K1 cells but not in 786-0 and Caki-1. The Bcl2/Bax ratio was increased in Caki-1, Caki-2 and SN12K1 cells but decreased in 786-0 cells. The increased IL-6 may contribute to sunitinib resistance either via VEGF-mediated angiogenesis or through shifting of the Bcl2/Bax balance in favour of anti-apoptosis.
Codon Publications
2018-08-10
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
text/html
application/pdf
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/108
10.15586/jkcvhl.2018.106
Journal of Kidney Cancer and VHL; Vol. 5 No. 3 (2018): Journal of Kidney Cancer and VHL; 1-9
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/108/214
https://jkcvhl.com/index.php/jkcvhl/article/view/108/215
https://jkcvhl.com/index.php/jkcvhl/article/view/108/216
Copyright (c) 2018 Hossam Kamli
oai:ojs.pkp.sfu.ca:article/109
2021-10-11T10:04:35Z
jkcvhl:KCREV
Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
Del Vecchio, Sharon J.
Ellis, Robert J.
cabozantinib
renal cell carcinoma
targeted therapy
tyrosine kinase inhibitor
Kidney Cancer
Oncology
Targeted Therapy
Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase III METEOR trial compared cabozantinib against everolimus as a second- or greater line therapy and found benefits in progression-free and overall survival, and the phase II CABOSUN trial compared cabozantinib against sunitinib as a first-line therapeutic and found benefits in terms of progression-free survival. This review briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma.
Codon Publications
2018-10-08
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/109
10.15586/jkcvhl.2018.109
Journal of Kidney Cancer and VHL; Vol. 5 No. 4 (2018): Journal of Kidney Cancer and VHL; 1-5
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/109/218
https://jkcvhl.com/index.php/jkcvhl/article/view/109/219
https://jkcvhl.com/index.php/jkcvhl/article/view/109/220
Copyright (c) 2018 Sharon Del Vecchio, Robert J Ellis
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/113
2021-10-12T13:03:32Z
jkcvhl:PHE
Clinical Syndromes and Genetic Screening Strategies of Pheochromocytoma and Paraganglioma
Liu, Peihua
Li, Minghao
Guan, Xiao
Yu, Anze
Xiao, Qiao
Wang, Cikui
Hu, Yixi
Zhu, Feizhou
Yin, Hongling
Yi, Xiaoping
Liu, Longfei
multiple endocrine neoplasia
von Hippel–Lindau syndrome
neurofibromatosis-1
pheochromocytoma
paraganglioma
Pheochromocytoma
Paraganglioma
Oncology
Pheochromocytomas (PCCs) are rare neuroendocrine tumors that originate from chromaffin cells of the adrenal medulla, and paragangliomas (PGLs) are extra-adrenal pheochromocytomas. These can be mainly found in clinical syndromes including multiple endocrine neoplasia (MEN), von Hippel–Lindau (VHL) syndrome, neurofibromatosis-1 (NF-1) and familial paraganglioma (FPGL). PCCs and PGLs are thought to have the highest degree of heritability among human tumors, and it has been estimated that 60% of the patients have genetic abnormalities. This review provides an overview of the clinical syndrome and the genetic screening strategies of PCCs and PGLs. Comprehensive screening principles and strategies, along with specific screening based on clinical symptoms, biochemical tests and immunohistochemistry, are discussed.
Codon Publications
2018-12-27
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/113
10.15586/jkcvhl.2018.113
Journal of Kidney Cancer and VHL; Vol. 5 No. 4 (2018): Journal of Kidney Cancer and VHL; 14-22
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/113/227
https://jkcvhl.com/index.php/jkcvhl/article/view/113/226
https://jkcvhl.com/index.php/jkcvhl/article/view/113/228
Copyright (c) 2018 Peihua Liu, Minghao Li, Xiao Guan, Anze Yu, Qiao Xiao, Cikui Wang, Yixi Hu, Feizhou Zhu, Hongling Yin, Xiaoping Yi, Longfei Liu
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/114
2021-10-10T10:35:50Z
jkcvhl:KCREV
Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?
Renner, Alex
Samtani, Suraj
Marín, Arnaldo
Burotto, Mauricio
cytoreductive nephrectomy
immunotherapy
metastatic renal cell carcinoma
sunitinib
surgical outlook
Kidney Cancer
Oncology
Cytoreductive nephrectomy has been an integral part of management in metastatic renal cell carcinoma for patients with good performance status, based on the benefit shown by prospective trials in the interferon era and retrospective trials in the targeted therapies era. Clinical Trial to Assess the Importance of Nephrectomy (CARMENA), the first prospective phase III trial comparing a targeted agent alone (sunitinib) versus nephrectomy plus sunitinib, has been recently published, showing non-inferiority for the nephrectomy-sparing arm. In this article, we discuss the impact of nephrectomy including its immune-mediated effects, surgical morbidity and mortality, and the clinical data supporting the indications of nephrectomy in order to analyze the CARMENA trial in context, with the aim to identify optimal strategies for different patient populations in the metastatic setting.
Codon Publications
2019-03-05
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/114
10.15586/jkcvhl.2019.114
Journal of Kidney Cancer and VHL; Vol. 6 No. 1 (2019): Journal of Kidney Cancer and VHL; 1-7
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/114/232
https://jkcvhl.com/index.php/jkcvhl/article/view/114/233
https://jkcvhl.com/index.php/jkcvhl/article/view/114/234
Copyright (c) 2019 Suraj Samtani
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/115
2021-10-10T11:49:28Z
jkcvhl:KCART
Trifecta Outcomes in Open, Laparoscopy or Robotic Partial Nephrectomy: Does the Surgical Approach Matter?
Mehra, Ketan
Manikandan, Ramanitharan
Dorairajan, Lalgudi Narayanan
Sreerag, Sreenivasan
Jain, Amit
Bokka, Sri Harsha
Partial Nephrectomy
Renal Cell Carcinoma
Renal Tumours
Robotic Partial Nephrectomy
Trifecta outcomes.
Kidney cancer
This retrospective study evaluated perioperative outcomes of open partial nephrectomy (OPN), laparoscopic partial nephrectomy (LPN), and robot-assisted partial nephrectomy (RAPN) and identified predictive factors of Trifecta achievement for renal tumors that underwent partial nephrectomy (PN) in a single institutional cohort. The study involved patients who underwent PN from January 2011 to July 2018. Trifecta was defined as absence of perioperative complications, no positive surgical margins, and ischemia time <30 min. Fifty-five PN procedures were reviewed: 28 OPN, 14 LPN, and 13 RAPN. OPN, LPN and RAPN had similar median tumor size (5.75, 5.25, and 5 cm), nephrometry score (7, 6, and 6), and preoperative creatinine (1.09, 1.1, and 1.1 mg/dl, respectively). Blood loss was higher for OPN (550 ml) than for LPN (400 ml) and RAPN (300 ml), P = 0.042. Drain was removed after 6 days in OPN which was higher than LPN and RAPN (4.5 and 4 days, respectively), P = 0.008. OPN, LPN, and RAPN had similar median operative time (190, 180, and 180 min, respectively), P = 0.438. Median postoperative stay for OPN, LPN, and RAPN was 5, 6.5, and 10 days, respectively. Trifecta outcomes of 73.1%, 64.3%, and 61.53% were achieved in OPN, LPN, and RAPN, respectively, P = 0.730. It was concluded that Trifecta outcomes had no significant difference among OPN, LPN, and RAPN. LPN can produce as good results as RAPN. Keeping in mind the cost-effectiveness, LPN holds an important position in developing countries where expenditure by patient is a major factor.
Codon Publications
2019-05-13
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
application/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/115
10.15586/jkcvhl.2019.115
Journal of Kidney Cancer and VHL; Vol. 6 No. 1 (2019): Journal of Kidney Cancer and VHL; 8-12
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/115/235
https://jkcvhl.com/index.php/jkcvhl/article/view/115/236
https://jkcvhl.com/index.php/jkcvhl/article/view/115/237
Copyright (c) 2019 Ketan Mehra, Manikandan Ramanitharan, Dorairajan Lalgudi Narayanan, Sreerag Sreenivasan, Amit Jain, Sri Harsha Bokka
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/121
2021-10-10T12:01:42Z
jkcvhl:KCART
Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases
Vaishampayan, Ulka
George, Julie
Vigneau, Fawn
comorbidities
kidney cancer
nephrectomy
prognostic factors
SEER registry
Patients without cytoreductive nephrectomy (CN) are inadequately represented in metastatic renal cell carcinoma (RCC) clinical trials. The characteristics that impact the decision of CN were explored in the SEER database. Data on primary, regional, or distant (metastatic) stage kid-ney cancer over the period 2000–2013 were extracted from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER-18) database. A sub-analysis of Metropolitan Detroit cases, to evaluate the influence of comorbidities, was conducted. Logistic regression was used to calculate the odds ratios, and Cox model was used to calculate hazard ratios; 37% of 21,052 metastatic RCC cases had CN performed. CN demonstrated significant survival advantage (HR = 0.31, 95% confidence interval [CI]: 0.30–0.33). Comorbidity data were available on 76% of distant RCC cases from the Detroit SEER database. Neither hypertension, diabetes mellitus nor the number of comorbidities (0, 1 or 2) had a statistically significant impact on the likelihood of CN. Majority of patients (63%) with distant-stage RCC do not undergo CN and have a median overall survival (OS) of 3 months as compared to a median OS of 18 months for patients who have undergone CN. Patient demographics and tumor characteristics make a significant impact on the incidence of CN. The impact of comorbidities (number and type) was modest and not statistically significant. The optimal management of patients with synchronous primary and metastatic RCC needs to be prospectively evaluated in the setting of contemporary systemic therapy.
Codon Publications
2019-10-28
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/121
10.15586/jkcvhl.2019.121
Journal of Kidney Cancer and VHL; Vol. 6 No. 1 (2019): Journal of Kidney Cancer and VHL; 13-25
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/121/245
https://jkcvhl.com/index.php/jkcvhl/article/view/121/246
https://jkcvhl.com/index.php/jkcvhl/article/view/121/247
Copyright (c) 2019 Ulka Vaishampayan, MD, Julie George, Fawn Vigneau
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/122
2021-10-10T07:45:26Z
jkcvhl:KCREV
Management of Renal Cell Carcinoma—Current Practice in Sub-Saharan Africa
Cassell, Ayun
Jalloh, Mohamed
Yunusa, Bashir
Ndoye, Medina
M. Mbodji, Mouhamadou
Diallo, Abdourahmane
Kouka, Saint Charles
Labou, Issa
Niang, Lamine
Gueye, Serigne M.
immuotherapy
management
radical nephrectomy
renal cell carcinoma
sub-saharan africa
There is a global variation in the incidence of renal masses with the developed nations having a greater incidence. About 80–90% of renal malignancies are renal cell carcinomas (RCC) which account for 2–4% of all cancers. In Africa and the Middle East, the age-standardized incidence for RCC is 1.8–4.8/100,000 for males and 1.2–2.2/100,000 for females. The management of renal cell cancer is challenging. A multidisciplinary approach is effective for diagnosis, staging, and treatment. Guidelines recommend active surveillance, thermal ablation, partial nephrectomy, radical nephrectomy, cytoreductive nephrectomy and immunotherapy as various modalities for various stages of RCC. However, open radical nephrectomy is most widely adopted as an option for treatment at various stages of the disease in sub-Saharan Africa due to its cost-effectiveness, applicability at various stages, and the reduced cost of follow-up. Nevertheless, most patients in the region present with the disease in the advanced stage and despite surgery the prognosis is poor.
Codon Publications
2019-12-02
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/122
10.15586/jkcvhl.2019.122
Journal of Kidney Cancer and VHL; Vol. 6 No. 2 (2019): Journal of Kidney Cancer and VHL; 1-9
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/122/249
https://jkcvhl.com/index.php/jkcvhl/article/view/122/250
https://jkcvhl.com/index.php/jkcvhl/article/view/122/251
Copyright (c) 2019 Ayun Kotokai Cassell, Mohamed Jalloh, Bashir Yunusa, Medina Ndoye, Mouhamadou Mbodji, Abdourahmane Diallo, Saint Charles Kouka, Issa Labou, Lamine Niang, Serigne M. Gueye
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/123
2023-07-30T12:16:01Z
jkcvhl:KCCR
Spontaneous Retroperitoneal Hemorrhage in a Patient with Acquired Cystic Kidney Disease
Kotb, Ahmed
Ismail, Asmaa
Elmansy, Hazem
Prowse, Owen
Shahrour, Walid
hemodialysis
lumbotomy
retroperitoneal hemorrhage
Spontaneous retroperitoneal hemorrhage (SRH) is a rare emergency. It is usually encountered in patients on hemodialysis and is associated with high rate of morbidity and mortality. This is a case from the emergency department. The patient had unstable vitals with SRH following dialysis. Immediate exploration and nephrectomy using transverse lateral lumbotomy incision were done. Patients on hemodialysis are at a risk of SRH and frequent surveillance is recommended. Acquired cystic kidney disease (ACKD) can develop in hemodialysis patients and put them at risk for bleeding. Transverse lateral lumbotomy may be a safe option for direct access to the kidney in emergency kidney surgery
Codon Publications
2020-04-16
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/123
10.15586/jkcvhl.2020.123
Journal of Kidney Cancer and VHL; Vol. 7 No. 1 (2020): Journal of Kidney Cancer and VHL; 1-4
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/123/257
https://jkcvhl.com/index.php/jkcvhl/article/view/123/259
https://jkcvhl.com/index.php/jkcvhl/article/view/123/258
Copyright (c) 2020 Ahmed Kotb, Asmaa Ismail, Hazem Elmansy, Walid Shahrour, Owen Prowse
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/124
2021-10-10T09:52:17Z
jkcvhl:KCART
Computed Tomography Imaging Characteristics of Histologically Confirmed Papillary Renal Cell Carcinoma—Implications for Ancillary Imaging
Walker, Jeffrey B.
Loloi, Justin
Birk, Alexander
Raman, Jay D.
CT
histology
Hounsfield
kidney
papillary
RCC
Low-attenuation renal lesions on non-contrast computed tomography (CT) are often considered to be benign cysts without need for further imaging. However, the papillary subtype of renal cell carcinoma (RCC) may have similar radiographic characteristics. A single-center retrospective review was therefore performed to identify extirpated papillary RCC (pRCC) specimens with correlation made to preoperative tumor imaging characteristics. A total of 108 pRCC specimens were identified of which 84 (27 type I, 17 type 2, 40 unspecified) had CT imaging available for review. Non-contrast CT was available for 73 tumors with 16 (22%) demonstrating Hounsfield units (HU) measurements fewer than 20 at baseline without differences between papillary subtypes. Mean attenuation following contrast administration was similar between papillary subtypes (45 HU for type 1 pRCC and 49 HU for type 2). This study highlights that pathologically proven pRCC is a heterogeneous entity in terms of density on preoperative CT imaging. A non-contrast CT scan with HU fewer than 20 may not be an adequate evaluation for incidental renal masses, as over 1 in 5 pRCCs demonstrate lower attenuation than this cutoff. Further study is needed to identify the appropriate role of ancillary imaging in the workup of seemingly benign-appearing renal lesions.
Codon Publications
2019-12-30
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/124
10.15586/jkcvhl.2019.124
Journal of Kidney Cancer and VHL; Vol. 6 No. 2 (2019): Journal of Kidney Cancer and VHL; 10-14
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/124/254
https://jkcvhl.com/index.php/jkcvhl/article/view/124/255
https://jkcvhl.com/index.php/jkcvhl/article/view/124/256
Copyright (c) 2019 Jeffrey B. Walker, Justin Loloi, Alexander Birk, Jay D. Raman
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/125
2023-07-30T12:12:22Z
jkcvhl:KCART
Nephrectomy Delay of More than 10 Weeks from Diagnosis Is Associated with Decreased Overall Survival in pT3 RCC
Zeng, Jiping
Batai, Ken
R. Lee, Benjamin
nephrectomy
overall survival
renal cell carcinoma (RCC)
surgical wait time (SWT)
In this study, we aimed to evaluate the impact of surgical wait time (SWT) on outcomes of patients with renal cell carcinoma (RCC), and to investigate risk factors associated with prolonged SWT. Using the National Cancer Database, we retrospectively reviewed the records of patients with pT3 RCC treated with radical or partial nephrectomy between 2004 and 2014. The cohort was divided based on SWT. The primary outcome was 5-year overall survival (OS). Logistic regression analysis was used to investigate the risk factors associated with delayed surgery. Cox proportional hazards models were fitted to assess relations between SWT and 5-year OS after adjusting for confounding factors. A total of 22,653 patients were included in the analysis. Patients with SWT > 10 weeks had higher occurrence of upstaging. Using logistic regression, we found that female patients, African-American or Spanish origin patients, treatment in academic or integrated network cancer center, lack of insurance, median household income of <$38,000, and the Charlson–Deyo score of ≥1 were more likely to have prolonged SWT. SWT > 10 weeks was associated with decreased 5-year OS (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.15–1.33). This risk was not markedly attenuated after adjusting for confounding variables, including age, gender, race, insurance status, Charlson–Deyo score, tumor size, and surgical margin status (adjusted HR, 1.13; 95% CI, 1.04–1.24). In conclusion, the vast majority of patients underwent surgery within 10 weeks. There is a statistically significant trend of increasing SWT over the study period. SWT > 10 weeks is associated with decreased 5-year OS.
Codon Publications
2021-06-14
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/125
10.15586/jkcvhl.v8i2.125
Journal of Kidney Cancer and VHL; Vol. 8 No. 2 (2021): Journal of Kidney Cancer and VHL; 27-33
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/125/322
https://jkcvhl.com/index.php/jkcvhl/article/view/125/324
https://jkcvhl.com/index.php/jkcvhl/article/view/125/323
Copyright (c) 2021 Jiping Zeng, Ken Batai, Benjamin Lee
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/127
2023-07-30T12:16:01Z
jkcvhl:ED
The Year in Review for Renal Cancer
Vaishampayan, Ulka
Review
Renal Cancer
The treatment of kidney cancer has made some remarkable strides over the last few years. Two regimens received Food and Drug Administration (FDA) approval, multiple biomarkers were reported to show promise, and further enhancement and refinement of the prognostic characteristics occurred. The combinations of anti-angiogenic tyrosine kinase inhibitors with immune checkpoint inhibitors have rapidly become the preferred therapies in the front-line setting of advanced renal cancer.
Codon Publications
2020-05-22
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/127
10.15586/jkcvhl.2020.127
Journal of Kidney Cancer and VHL; Vol. 7 No. 1 (2020): Journal of Kidney Cancer and VHL; 5-6
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/127/262
https://jkcvhl.com/index.php/jkcvhl/article/view/127/263
https://jkcvhl.com/index.php/jkcvhl/article/view/127/264
Copyright (c) 2020 Ulka Vaishampayan, MD
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/129
2023-07-30T12:12:45Z
jkcvhl:PHE
Large Retroperitoneal Paraganglioma Associated with Germline Mutation of the Succinate Dehydrogenase Gene
Chen, Wen Min
Olson, Philip
Arcot, Rohith
Nguyen, Huy
Quereshi, Faisal
Kokenakes, Courtney
Cher, Michael L.
incidentaloma
paraganglioma
pheochromocytoma
retroperitoneal tumor
SDHB gene mutation
Paragangliomas (PGLs) are rare neural tumors that can be benign or malignant and often associated with familial syndromes. We present a case of a 23-year-old male with a large retroperitoneal PGL found incidentally during the workup of elevated liver enzymes. After surgical excision, the patient was found to have an autosomal dominant mutation in the succinate dehydrogenase B (SDHB) gene, which when compared to sporadic PGLs or other familial syndromes is associated with a higher risk of tumor recurrence, occult metastasis, and development of other cancers. The patient’s first-degree relatives were recommended to undergo screening for the genetic mutation.
Codon Publications
2021-01-25
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/129
10.15586/jkcvhl.v8i1.129
Journal of Kidney Cancer and VHL; Vol. 8 No. 1 (2021): Journal of Kidney Cancer and VHL; 12-18
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/129/301
https://jkcvhl.com/index.php/jkcvhl/article/view/129/303
https://jkcvhl.com/index.php/jkcvhl/article/view/129/302
Copyright (c) 2021 Wen Chen, Philip Olson, Rohith Arcot, Huy Nguyen, Faisal Qureshi, Courtney Kokenakes, Michael Cher
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/130
2023-07-30T12:14:52Z
jkcvhl:KCCR
Renal Cell Carcinoma with Direct Extension into the Gonadal Vein, Uterus, Fallopian Tube, and Bilateral Ovaries: A Case Report
Sweigert, Sarah E.
Bajic, Petar
Aragao, Alessa
Picken, Maria
Woods, Michael E.
Renal cell carcinoma (RCC) with invasion into the renal vein is well described; however, invasion into the gonadal vein is a rare event with less than five cases reported in the literature. RCC occasionally presents with metastasis to the ovaries or the fallopian tubes, although this is also a rare occurrence. We present a case of locally advanced left RCC with direct extension into the ipsilateral gonadal vein with extension into the bilateral ovaries and uterus, which has not been previously described. Computed tomography (CT) in a 72-year-old female with a 35-pound weight loss indicated the presence of a 16-cm left renal mass with caudal tumor extension through the left gonadal vein and regional lymph-adenopathy. There was no evidence of distant metastasis, and she underwent an open left radical nephrectomy. Intraoperatively, she was found to have direct extension of the tumor through the left gonadal vein into the uterus, bilateral ovaries, and the left fallopian tube. All visible dis-ease was resected, and retroperitoneal and pelvic lymphadenectomy were performed. The patient had an uneventful hospital course. Pathology revealed clear cell RCC, Fuhrman grade 3. The final pathologic stage was pT4N1M1. The patient was ultimately noted to have pulmonary metastasis and was treated with immunotherapy with no evidence of disease progression.
Codon Publications
2020-08-14
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/130
10.15586/jkcvhl.2020.130
Journal of Kidney Cancer and VHL; Vol. 7 No. 3 (2020): Journal of Kidney Cancer and VHL; 1-4
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/130/278
https://jkcvhl.com/index.php/jkcvhl/article/view/130/280
https://jkcvhl.com/index.php/jkcvhl/article/view/130/279
Copyright (c) 2020 Sarah Sweigert, Petar Bajic, Alessa Aragao, Maria Picken, Michael E. Woods
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/131
2023-07-30T12:14:52Z
jkcvhl:KCREV
Renal Manifestations of Tuberous Sclerosis Complex
Nair, Nikhil
Chakraborty, Ronith
Mahajan, Zubin
Sharma, Aditya
K. Sethi, Sidharth
Raina, Rupesh
Tuberous sclerosis complex (TSC) is a genetic condition caused by a mutation in either the TSC1 or TSC2 gene. Disruption of either of these genes leads to impaired production of hamartin or tuberin proteins, leading to the manifestation of skin lesions, tumors, and seizures. TSC can manifest in multiple organ systems with the cutaneous and renal systems being the most commonly affected. These manifestations can secondarily lead to the development of hypertension, chronic kidney disease, and neurocognitive declines. The renal pathologies most commonly seen in TSC are angiomyolipoma, renal cysts, and less commonly, oncocytomas. In this review, we highlight the current understanding on the renal manifestations of TSC along with current diagnosis and treatment guidelines.
Codon Publications
2020-08-27
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/131
10.15586/jkcvhl.2020.131
Journal of Kidney Cancer and VHL; Vol. 7 No. 3 (2020): Journal of Kidney Cancer and VHL; 5-19
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/131/284
https://jkcvhl.com/index.php/jkcvhl/article/view/131/286
https://jkcvhl.com/index.php/jkcvhl/article/view/131/285
Copyright (c) 2020 Nikhil Nair, Ronith Chakraborty , Zubin Mahajan, Aditya Sharma , Siddarth K. Sehti, Rupesh Raina
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/132
2023-07-30T12:13:57Z
jkcvhl:KCART
Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer
Vaishampayan, Ulka
Shah, Harsh
Asad, Mohammad F.
Shi, Dongping
Dickow, Brenda
Suisham, Stacey
Domina, Jason
Cher, Michael L.
Samantray, Julie
Aoun, Hussein D.
kidney cancer
immunotherapy
clear cell
metastases
Involvement of the adrenal gland in kidney cancer represents a unique site of metastasis with a distinct clinical course. The cases are typically resistant to immune therapy and need local therapy management. A case series of patients with adrenal metastases was reviewed to highlight the nuances of clinical course and therapy. We reviewed renal cancer carcinoma (RCC) cases with adrenal metastases at Karmanos Cancer Center, Detroit MI. Medical records were reviewed to collect relevant case information. Next-generation sequencing, tumor mutation burden testing, and programmed death ligand biomarkers were evaluated in five cases. Twelve cases were reviewed; all were males with a median age of 49.5 years. Three patients presented with adrenal metastases only and were treated with local therapy. Three received interleukin-2 (IL-2). One patient relapsed with bilateral adrenal lesions after 11 years of remission, post-IL-2 therapy. Five cases received immune checkpoint inhibitor (ICI) and one received antivascular therapy. ICI therapy was followed by ablation of residual adrenal metastases in three patients. Genomic profiling was available in five cases. All were BAP1 and PD-L1 negative. Pathogenic mutations in PBRM1, SETD2, and VHL were noted. All patients with residual adrenal metastases responded to antivascular therapies or to local ablation. One patient died 17 years after diagnosis and 11 patients are alive at a median follow-up of 9.5 years. Adrenal metastases in RCC have a distinct clinical course. They can represent a sanctuary site of relapse/residual disease following treatment with immune therapy. Management with local therapy can induce durable remissions. Systemic management with antivascular therapies also demonstrated favorable responses. Further investigation should focus on the unique clinical course and optimal management of adrenal metastases in kidney cancer.
Codon Publications
2020-10-12
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/132
10.15586/jkcvhl.2020.132
Journal of Kidney Cancer and VHL; Vol. 7 No. 4 (2020): Journal of Kidney Cancer and VHL; 1-7
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/132/289
https://jkcvhl.com/index.php/jkcvhl/article/view/132/291
https://jkcvhl.com/index.php/jkcvhl/article/view/132/290
Copyright (c) 2020 Ulka Vaishampayan, MD, Harsh Shah, Mohammad F Asad, Dongping Shi, Brenda Dickow, Jason Domina, Michael L. Cher, Julie Samantray, Hussein D. Aoun
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/133
2023-07-30T12:15:30Z
jkcvhl:SC
Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors
Loloi, Justin
Shingleton, W. Bruce
Nakada, Stephen Y.
Zagoria, Ronald J.
Landman, Jaime
R. Lee, Benjamin
F. Matin, Surena
Ahrar, Kamran
J. Leveillee, Raymond
Cadeddu, Jeffrey A.
D. Raman, Jay
cryoablation
radiofrequency ablation
renal cell carcinoma
nephrectomy
recurrences
Management of residual or recurrent disease following thermal ablation of renal cortical tumors includes surveillance, repeat ablation, or surgical extirpation. We present a multicenter experience with regard to the management of this clinical scenario. Prospectively maintained databases were reviewed to identify 1265 patients who underwent cryoablation (CA) or radiofrequency ablation (RFA) for enhancing renal masses. Disease persistence or recurrence was classified into one of the three categories: (i) residual disease in ablation zone; (ii) recurrence in the ipsilateral renal unit; and (iii) metastatic/extra-renal disease. Seventy seven patients (6.1%) had radiographic evidence of disease persistence or recurrence at a median interval of 13.7 months (range, 1–65 months) post-ablation. Distribution of disease included 47 patients with residual disease in ablation zone, 29 with ipsilateral renal unit recurrences (all in ablation zone), and one with metastatic disease. Fourteen patients (18%) elected for surveillance, and the remaining underwent salvage ablation (n = 50), partial nephrectomy (n = 5), or radical nephrectomy (n = 8). Salvage ablation was successful in 38/50 (76%) patients, with 12 failures managed by observation (3), tertiary ablation (6), and radical nephrectomy (3). At a median follow-up of 28 months, the actuarial cancer-specific survival and overall survival in this select cohort of patients was 94.8 and 89.6%, respectively.
Codon Publications
2020-06-09
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/133
10.15586/jkcvhl.2020.133
Journal of Kidney Cancer and VHL; Vol. 7 No. 2 (2020): Journal of Kidney Cancer and VHL; 1-5
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/133/268
https://jkcvhl.com/index.php/jkcvhl/article/view/133/270
https://jkcvhl.com/index.php/jkcvhl/article/view/133/269
Copyright (c) 2020 Justin Loloi, Bruce Shingleton, Stephen Nakada, Ronald Zagoria, Jaime Landman, Benjamin Lee, Surena Matin, Raymond Leveillee, Jeffrey Cadeddu, Jay Raman
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/134
2023-07-30T12:14:52Z
jkcvhl:KCART
Histologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass Biopsy
M. Nahouraii, Lauren
L. Allen, Jordan
B. Merrill, Suzanne
Lehman, Erik
G. Kaag, Matthew
Raman, Jay D.
heterogeneity
histology
renal cell carcinoma
renal mass biopsy
renal tumors
Pathologic characteristics of extirpated renal cell carcinoma (RCC) specimens <7 cm were reviewed to get better information on technical nuances of renal mass biopsy (RMB). Specimens were stratified according to tumor stage, nuclear grade, size, histology, presence of lymphovascular invasion (LVI), necrosis, and sarcomatoid features. When considering pT1 (0–7 cm) tumors, pT1b (4–7 cm) RCC masses were more likely to have necrosis (43% vs 16%, P < 0.001), LVI (6% vs 2%, P = 0.024), high-grade nuclear elements (29% vs 17%, P < 0.001), and sarcomatoid features (2% vs 0%, P = 0.006) compared with pT1a (0–4 cm) tumors. Additionally, pT3a tumors were more highly associated with necrosis (P = 0.005), LVI, sarcomatoid features, and high-grade disease (P for all < 0.001) when compared to pT1 masses. For masses ≤ 4 cm, pT3a cancers were more likely to demonstrate necrosis (38% vs 16%, P < 0.001), LVI (22% vs 2%, P < 0.001), high-grade nuclear elements (45% vs 17%, P < 0.001), and sarcomatoid features (12% vs 0%, P < 0.001) compared to pT1a tumors. Similarly, for masses 4–7 cm, pathologic T3a tumors were significantly more likely to have sarcomatoid features (12% vs 2%, P = 0.006) and LVI (22% vs 6%, P = 0.003) compared to pT1b tumors. In summary, pT3a tumors and those RCC masses >4 cm exhibit considerable histologic heterogeneity and may harbor elements that are not easily appreciated with limited renal sampling. Therefore, if RMB is considered for renal masses greater than 4 cm or those that abut sinus fat, a multi-quadrant biopsy approach is necessary to ensure adequate sampling and characterization of the mass.
Codon Publications
2020-08-25
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/134
10.15586/jkcvhl.2020.134
Journal of Kidney Cancer and VHL; Vol. 7 No. 3 (2020): Journal of Kidney Cancer and VHL; 20-25
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/134/281
https://jkcvhl.com/index.php/jkcvhl/article/view/134/283
https://jkcvhl.com/index.php/jkcvhl/article/view/134/282
Copyright (c) 2020 Lauren M. Nahouraii, Jordan L. Allen, MD, Suzanne B. Merrill, MD, Erik B. Lehman, Matthew G. Kaag, Jay D. Raman, MD, FACS
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/135
2023-07-30T12:16:01Z
jkcvhl:KCCR
Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation
Vlachostergios, Panagiotis J.
angiogenesis
molecular biomarker
mutation
immunotherapy
renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) represents the most common subtype of renal cell carcinoma (RCC). In spite of recent advances in the treatment armamentarium and outcomes with the combined use of immune checkpoint and angiogenesis inhibitors, prediction of responses and selection of patients remain a challenge. This is a case of ccRCC with recurrence to the liver 1 year following right radical nephrectomy, who rapidly progressed on frontline therapy with axitinib/pembrolizumab. The clinical course and targeted tumor sequencing findings are discussed. In addition to established clinical prognostication in RCC, several surrogate markers of efficacy or/and resistance have been proposed for immunotherapy or/and anti-angiogenic therapy. Since the majority of patients will still progress after these combinations, it is becoming increasingly important to develop robust predictive biomarkers to guide patient selection and sequencing of targeted therapies.
Codon Publications
2020-06-02
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/135
10.15586/jkcvhl.2020.135
Journal of Kidney Cancer and VHL; Vol. 7 No. 1 (2020): Journal of Kidney Cancer and VHL; 7-11
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/135/265
https://jkcvhl.com/index.php/jkcvhl/article/view/135/267
https://jkcvhl.com/index.php/jkcvhl/article/view/135/266
Copyright (c) 2020 Panagiotis Vlachostergios
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/148
2023-07-30T12:15:30Z
jkcvhl:KCCR
A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy
Yonese, Ichiro
Ito, Masaya
Takemura, Kosuke
Kamai, Takao
Koga, Fumitaka
Metastatic Hereditary Leiomyomatosis
Renal Cell Cancer Syndrome
Renal Cell Carcinoma
Cytoreductive Nephrectomy
Axitinib
Nivolumab
Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) associated renal cell carcinoma (RCC) is an aggressive form of type 2 papillary RCC caused by deficiency of the fumarate hydratase gene. For patients with metastatic disease, no standard treatment has been established with dismal prognosis. We report a case of metastatic HLRCC-associated RCC in a 65-year-old Japanese male whose clinical features mimicked advanced renal pelvic cancer. A durable response was achieved with a sequence of axitinib and nivolumab after cytoreductive and diagnostic nephrectomy. Their potential therapeutic roles in the management of metastatic HLRCC-associated RCC have been discussed based on its molecular and biological backgrounds.
Codon Publications
2020-07-20
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/148
10.15586/jkcvhl.2020.148
Journal of Kidney Cancer and VHL; Vol. 7 No. 2 (2020): Journal of Kidney Cancer and VHL; 6-10
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/148/271
https://jkcvhl.com/index.php/jkcvhl/article/view/148/272
https://jkcvhl.com/index.php/jkcvhl/article/view/148/273
Copyright (c) 2020 Ichiro Yonese, Masaya Ito, Kosuke Takemura, Takao Kamai, Fumitaka Koga, MD,PhD
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/149
2023-07-30T12:15:30Z
jkcvhl:KCART
Surgical Outcome of Renal Cell Carcinoma with Tumor Thrombus Extension into Inferior Vena Cava and Right Atrium (Beating Heart Removal of Level 4 Thrombus): A Challenging Scenario
Khawaja, Abdul Rouf
Sofi, Khalid
Dar, Yasir
Khateeb, Muzaain
Magray, Javeed
Waheed, Abdul
Malik, Sajad
Bhat, Arif Hamid
Wani, Mohd. Saleem
Bhat, Akbar
renal cell carcinoma
tumor thrombus
cardiopulmonary bypass
intraoperative transesophageal echocardiography
Aim: “To evaluate oncological and surgical outcomes of different levels of tumor thrombus and tumor characteristics secondary to renal cell carcinoma (RCC)”.
Materials and Methods: Retrospective review from 2013 to 2020 of 34 patients who underwent radical nephrectomy with thrombectomy for RCC with tumor thrombus extending into the inferior vena cava (IVC) and right atrium (RA) at our center. Level I and most level II tumors were removed using straight forward occluding maneuvers with control of the contralateral renal vein. None of the patients had level III tumor extensions in our study group. For level IV thrombus, a beating heart surgery using a simplified cardiopulmonary bypass (CPB) technique was used for retrieval of thrombus from the right atrium.
Results: “Of the 34 patients with thrombus”, 19 patients had level I, 12 patients had level II, none had level III, and three patients had level IV thrombus. Two patients required simplified CPB. Another patient with level IV thrombus CPB, was not attempted in view of refractory hypotension intraoperatively. Pathological evaluation showed clear-cell carcinoma in 67.64%, papillary carcinoma in 17.64%, chromophobe in 5.8%, and squamous cell carcinoma in 8.8% of cases. Left side thrombectomy was difficult surgically, whereas right side thrombectomy did not have any survival advantage. Mean blood loss during the procedure was 325 mL, ranging from 200 to 1000 mL, and mean operative time was 185 min, ranging from 215 to 345 min. The immediate postoperative mortality was 2.9%. Level I thrombus had better survival compared to level II thrombus.
Conclusion: Radical nephrectomy with tumor thrombectomy remains the mainstay of treatment in RCC with inferior venacaval extension. The surgical approach and outcome depends on primary tumor size, location, level of thrombus, local invasion of IVC, any hepato-renal dysfunction or any associated comorbidities. The higher the level of thrombus, the greater is the need for prior optimization and the adoption of a multidisciplinary approach for a successful surgical outcome.
Codon Publications
2020-07-31
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/149
10.15586/jkcvhl.2020.149
Journal of Kidney Cancer and VHL; Vol. 7 No. 2 (2020): Journal of Kidney Cancer and VHL; 11-17
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/149/274
https://jkcvhl.com/index.php/jkcvhl/article/view/149/276
https://jkcvhl.com/index.php/jkcvhl/article/view/149/275
Copyright (c) 2020 Abdul Khawaja, Khalid Sofi, Yasir Dar, Muzaain Khateeb, Javeed Magray, Abdul Waheed, Sajad Malik, Arif Hamid Bhat, Mohd. Saleem Wani, Akbar Bhat
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/151
2023-07-30T12:12:45Z
jkcvhl:KCART
Bilateral Single-Stage Nephrectomy for Synchronous Bilateral Renal Cell Carcinoma
Kotb, Ahmed
Alaref, Amer
Kisselgoff, David
Ismail, Asmaa
Rozenberg, Radu
Burute, Nishigandha
Shahrour, Walid
Prowse, Owen
Elmanasy, Hazem
RCC
Lumbotomy
Nephrectomy
Bilateral synchronous renal cell carcinoma (RCC) is uncommonly encountered. Debate exists among urologists in managing these cases in a single surgery versus staged surgeries. We aim to report our experience in managing encountered cases using single-stage surgeries. Retrospective collection of cases with pathologically confirmed RCC that had single-stage bilateral renal surgery over the past 2 years. Three cases were identified. Patients were managed using bilateral transverse lateral lumbotomy. All patients did not have intraoperative or postoperative complications. Kidney function stayed stable after surgery. Single-stage bilateral renal surgery is a safe procedure. Bilateral transverse lateral lumbotomy allows for a fast and safe surgery with minimal complications. There is a possible histological dis-concordance in bilateral synchronous RCC.
Codon Publications
2021-01-25
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/151
10.15586/jkcvhl.v8i1.151
Journal of Kidney Cancer and VHL; Vol. 8 No. 1 (2021): Journal of Kidney Cancer and VHL; 7-11
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/151/304
https://jkcvhl.com/index.php/jkcvhl/article/view/151/306
https://jkcvhl.com/index.php/jkcvhl/article/view/151/305
Copyright (c) 2021 Ahmed Kotb, Amer Alaref, David Kisselgoff, Asmaa Ismail, Radu Rozenberg, Nishigandha Burute, Walid Shahrour, Owen Prowse, Hazem Elmansy
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/153
2023-07-30T12:13:57Z
jkcvhl:KCCR
Do Primitive Neuroectodermal Tumors of the Kidney Have a Predilection for Inferior Vena Cava Involvement? A Case Series and Review of the Literature
Hota, Sovan
Kalra, Sidhartha
Narayanan Dorairajan, Lalgudi
Manikandan, Ramanitharan
Sreenivasan, Sreerag Kodakkattil
immunohistochemistry
IVC thrombus
multimodality treatment
PNET
renal pelvis PNET
renal PNET
The primitive neuroectodermal tumor (PNET) of the kidney is an extremely rare neoplasm, the diagnosis of which mainly depends upon histopathology, immunohistochemistry (IHC), and cytogenetics. A handful of cases reported in the literature mention about aggressive features of this neoplasm. The purpose of our study was to review our experience in not only the diagnosis and management of the patients with renal PNET but also to highlight its propensity to involve inferior vena cava (IVC) and also present a rare occurrence of Ewing’s sarcoma (ES)/PNET of the renal pelvis.
The clinical, operative, and histopathology records of four patients of renal PNET treated between January 2017 and December 2019 were reviewed and data analyzed concerning the available literature. Out of the four patients treated, two had level III and IV IVC thrombus, and one had dense desmoplastic adhesions with the IVC wall. One of the cases had a rare presentation of ES/PNET of the renal pelvis. All patients were managed surgically, while only one patient received adjuvant chemotherapy and following up with remission for the last 2 years and 4 months. On IHC, cluster of differentiation-99 (CD-99) was positive in all patients, and three were positive for Friend leukemia integration-1. PNET of the kidney is primarily an immunohistopathological diagnosis. This neoplasm has an increased propensity for the local invasion of surrounding structures. A multimodality approach with surgery, chemotherapy, and radiotherapy could offer better outcomes, although the prognosis of these tumors remains poor.
Codon Publications
2020-10-12
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/153
10.15586/jkcvhl.2020.153
Journal of Kidney Cancer and VHL; Vol. 7 No. 4 (2020): Journal of Kidney Cancer and VHL; 8-16
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/153/292
https://jkcvhl.com/index.php/jkcvhl/article/view/153/294
https://jkcvhl.com/index.php/jkcvhl/article/view/153/293
Copyright (c) 2020 Sovan Hota, Sidhartha Kalra, Dorairajan Lalgudi Narayanan, Ramanitharan Manikandan, Sreerag Kodakkattil Sreenivasan
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/154
2023-07-30T12:12:45Z
jkcvhl:KCART
Epidemiology and Clinicopathological Profile of Renal Cell Carcinoma: A Review from Tertiary Care Referral Centre
Pallagani, Likhiteswer
Choudhary, Gautam Ram
Pandey, Himanshu
Madduri, Vijay K.S.
Singh, Mahendra
Gupta, Prateek
Shrivastava, Nikita
Baid, Gaurav
Rao, Meenakshi
Nalwa, Aasma
Pareek, Puneet
Misra, Sanjeev
epidemiology
laparoscopy
minimally invasive surgery
paraneoplastic syndromes
renal cell carcinoma
robotic surgery
Western India
Renal cell carcinoma (RCC) accounts for 3% of all adult cancers and 85% of all kidney tumours. Incidence of RCC is lower in Asian region, particularly in India, probably due to lack of reporting. Most of the data about RCC are from Western countries; and data from India are scarce, especially regarding para-neoplastic syndromes. We sought to determine the epidemiology, clinicopathological profile and management of RCCin a tertiary care centre in Western India.
This was a retrospective study that involved data analysis of records of RCC patients who presented to our institution from April 2016 to February 2020. Laboratory investigations, including tests for paraneoplastic syndrome (PNS), and relevant radiologic investigations were performed and treatment was offered according to the stage, patient factors and available modalities.
A total 142 RCC patients were included in the study. The median age of presentation was 58 years. Most of the patients (67%) were symptomatic, and 33% of the patients were asymptomatic, and the RCC was diagnosed incidentally. A large number of patients (56.3%) had PNS. The most common histopathologic type of RCC was clear cell carcinoma (68.8%), followed by papillary (20%) and chromophobe (8%) carcinoma. 40% of carcinomas with sarcomatoid differentiation were seen in patients under 50 years of age. Two cases of multicystic RCC were both seen in patients less than 50 years of age. 65.5% of the patients presented at Stage 1 and 2. Most surgeries (71.2%) were done in a minimally invasive manner.
A significant number of patients were asymptomatic, in which RCC was detected incidentally. The age of presentation was earlier, yet the patients had a higher tumour stage. More than half of the patients had PNSs. Despite growing trend towards Western data, the significantly higher number of patients with PNSs and early age of presentation suggest inherent differences in tumour biology, possibly related to differences in genetic and environmental factors.
Codon Publications
2021-01-20
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/154
10.15586/jkcvhl.v8i1.154
Journal of Kidney Cancer and VHL; Vol. 8 No. 1 (2021): Journal of Kidney Cancer and VHL; 1-6
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/154/298
https://jkcvhl.com/index.php/jkcvhl/article/view/154/300
https://jkcvhl.com/index.php/jkcvhl/article/view/154/299
Copyright (c) 2021 Likhiteswer Pallagani , Gautam Ram Choudhary, Himanshu Pandey, Vijay Kumar Sarma Madurri, Mahendra Singh, Prateek Gupta, Nikita Shrivastava, Gaurav Baid, Meenakshi Rao, Aasma Nalwa, Puneet Pareek, Sanjeev Mishra
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/156
2023-07-30T12:13:57Z
jkcvhl:KCREV
Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma
Toth, Alexander T.
Cho, Daniel C.
HIF
immunotherapy
renal cell carcinoma
systemic therapy
TKI
Multiple combinational regimens have recently been approved and are now considered the standard of care for patients with advanced clear cell renal cell carcinoma (RCC). Several additional combinational regimens are deep in clinical assessment and are likely to soon join the crowded front-line therapeutic landscape. Most of these regimens are combinations of agents already approved as single-agents in RCC including tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors. While these new front-line regimens are associated with reliably high response rates and prolonged survival, complete and durable remissions remain limited to a small subset of patients and the vast majority of patients continue to require subsequent therapy. The need for the continued development of novel agents in RCC persists and efforts have focused on agents targeting the molecular biology of clear cell RCC and novel immunotherapies including cytokines. In this review, we discuss the progress in the development of these novel therapies in the context of the evolving standard of care for patients with advanced clear cell RCC.
Codon Publications
2020-12-14
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/156
10.15586/jkcvhl.2020.156
Journal of Kidney Cancer and VHL; Vol. 7 No. 4 (2020): Journal of Kidney Cancer and VHL; 17-26
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/156/295
https://jkcvhl.com/index.php/jkcvhl/article/view/156/297
https://jkcvhl.com/index.php/jkcvhl/article/view/156/296
Copyright (c) 2020 Alexander Toth, Daniel Cho
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/158
2022-03-30T07:12:10Z
jkcvhl:SC
Optical Coherence Tomography Angiography of Early Stage 1a Retinal Hemangioblastoma in Von-Hippel-Lindau
Goswami, Ananya
Surve, Abhidnya
Venkatesh, Pradeep
hemangioblastoma
OCTA
retinal capillary hemangioblastoma
VHL
Von-Hippel-Lindau (VHL) syndrome is characterized by focal vasoproliferative tumors of retinal capillaries called retinal capillary hemangioblastomas (RCH). These tumors are initially small and can be easily missed if not looked for carefully. As they grow, these tumors are more demanding to treat and hence the importance of detecting them early and treating them. Herein, we describe and review the optical coherence tomography angiography (OCTA) of the early-stage lesion, which suggested the involvement of superficial and a deeper retinal capillary plexus. In addition, to helping us detect these lesions earlier, OCTA may also help to understand the in vivo changes occurring at an earlier phase.
Codon Publications
2021-09-23
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/158
10.15586/jkcvhl.v8i3.158
Journal of Kidney Cancer and VHL; Vol. 8 No. 3 (2021): Journal of Kidney Cancer and VHL; 15-18
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/158/340
https://jkcvhl.com/index.php/jkcvhl/article/view/158/342
https://jkcvhl.com/index.php/jkcvhl/article/view/158/341
Copyright (c) 2021 Ananya Goswami, Abhidnya Surve, Pradeep Venkatesh
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/161
2023-07-30T12:12:45Z
jkcvhl:KCCR
Thrombotic Microangiopathy Associated with Pazopanib in a Kidney Transplant Recipient
Kalla, Shabana
Ellis, Robert J.
Campbell, Scott
Doucet, Brian
Isbel, Nicole
Tie, Bibiana
Jegatheesan, Dev
kidney transplant
pazopanib
thrombotic microangiopathy
vascular endothelial growth factor inhibitors
Thrombotic microangiopathy (TMA) is characterised by abnormalities in the walls of arterioles and capillaries, precipitated by hereditary or acquired characteristics, and culminating in microvascular thrombosis because of dysregulated complement activity. A number of drugs can precipitate TMA, including vascular endothelial growth factor (VEGF) inhibitors, because of their effects on endothelial repair. Pazopanib is a VEGF inhibitor used for the treatment of renal cell carcinoma (RCC); it is uncommonly associated with TMA. A 52-year-old male, 5 years post his second kidney transplant secondary to immunoglobulin (Ig) A nephropathy, presented with hypertension, fluid overload, and worsening graft function (peak creatinine 275 μmol/L, baseline 130–160 μmol/L) and nephrotic range proteinuria 2 months after commencing pazopanib for metastatic RCC. His maintenance immunosuppression included ciclosporin, mycophenolate, and prednisolone. Haematological parameters were unremarkable. Allograft biopsy demonstrated glomerular and arteriolar changes consistent with chronic active TMA, with overlying features of borderline cellular rejection. He was treated with intravenous methylprednisolone 250 mg for 3 days and commenced on irbesartan 75 mg daily. Drug-induced TMA from pazopanib was suspected, particularly given the documented association with other tyrosine kinase inhibitors (TKIs). In consultation with his medical oncologist, pazopanib was ceased, and an alternate TKI cabozantinib was commenced. Serum creatinine remained <200 μmol/L 3 months after admission. This is the first reported biopsy-proven case of TMA attributed to pazopanib in a kidney transplant recipient. With increasing clinical indications for and availability of TKIs, clinicians need to be aware of their association with TMA events in kidney transplant recipients, who are already susceptible to TMA due to abnormal vasculature, infectious triggers, ischaemia-reperfusion injury, and use of calcineurin inhibitor.
Codon Publications
2021-03-24
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/161
10.15586/jkcvhl.v8i1.161
Journal of Kidney Cancer and VHL; Vol. 8 No. 1 (2021): Journal of Kidney Cancer and VHL; 25-31
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/161/310
https://jkcvhl.com/index.php/jkcvhl/article/view/161/312
https://jkcvhl.com/index.php/jkcvhl/article/view/161/311
Copyright (c) 2021 Shabana Kalla, Robert J Ellis, Scott Campbell, Brian Doucet, Nicole Isbel, Bibiana Tie, Dev Jegatheesan
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/162
2023-07-30T12:11:22Z
jkcvhl:KCCR
Primary Chondrosarcoma in L-shaped Crossed Fused Renal Ectopia Coexisting with Papillary Urothelial Carcinoma in Urinary Bladder – An Enigmatic Entity with Poor Prognosis
Kumar, Mayank
Nalwa, Aasma
Yadav, Taruna
Elhence, Poonam
Pandey, Himanshu
Rao, Meenakshi
chondrosarcoma
kidney
renal ectopia
urinary bladder
urothelial carcinoma
Primary renal chondrosarcomas are rare tumors that are high-grade in nature and, unfortunately, have poorly understood pathogenesis and extremely low prognosis. The coexistence of a discrete malignancy in the urinary bladder is even rarer, with the occurrence of distinct papillary urothelial carcinoma in the urinary bladder in this case. The clinical presentation is nonspecific, and the primary radiological investigations have a limited scope in providing specific diagnosis of this entity. The final diagnosis is possible on thorough histopathological examination of the resected specimen, which requires extensive sampling and meticulous reporting. As of now, the only way to achieve a better prognosis is by early diagnosis. It is necessary to keep the possibility of occurrence of sarcomas at rare sites in the differential diagnoses. The cytogenetic and molecular abnormalities associated with this entity need to be elucidated to achieve a more satisfactory outcome concerning the overall management of the patient.
Codon Publications
2021-11-28
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/162
10.15586/jkcvhl.v9i1.162
Journal of Kidney Cancer and VHL; Vol. 9 No. 1 (2022): Journal of Kidney Cancer and VHL; 9-14
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/162/370
https://jkcvhl.com/index.php/jkcvhl/article/view/162/372
https://jkcvhl.com/index.php/jkcvhl/article/view/162/371
Copyright (c) 2021 Dr Mayank Kumar, Dr Aasma Nalwa, Dr Taruna Yadav, Dr Poonam Elhence, Dr Himanshu Pandey, Dr Meenakshi Rao
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/168
2022-03-30T07:11:58Z
jkcvhl:KCCR
Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma
Nwabundo, Anusim
Damilola, Gbadebo
Olabisi, Afolayan-Oloye
Ishmael, Jaiyesimi
case study
immunotherapy
renal cell carcinoma
sarcomatoid differentiation
Sarcomatoid differentiation is a rare and aggressive histologic subtype with poor prognosis, seen in several malignancies. In sarcomatoid renal cell carcinoma (RCC), the degree of sarcomatoid differentiation and the stage at presentation determines the prognosis. Despite resection, chemotherapy and targeted therapy response is modest, with relapse usually occurring within a few months. We present a case of a gentleman with sarcomatoid RCC managed with pembrolizumab, who has had no evidence of recurrence for over 4 years since the last dose of immunotherapy. RCCs with sarcomatoid differentiation have a high presence of programmed cell death protein 1 and programmed cell death ligand 1 in T cells and tumor cells, respectively, making immunotherapy an attractive option in this setting. Clinical trials are ongoing to further define the benefit of immunotherapy in sarcomatoid RCC.
Codon Publications
2021-10-26
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/168
10.15586/jkcvhl.v8i4.168
Journal of Kidney Cancer and VHL; Vol. 8 No. 4 (2021): Journal of Kidney Cancer and VHL; 38-42
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/168/364
https://jkcvhl.com/index.php/jkcvhl/article/view/168/366
https://jkcvhl.com/index.php/jkcvhl/article/view/168/365
Copyright (c) 2021 Nwabundo Anusim, Damilola Gbadebo, Olabisi Afolayan-Oloye, Ishmael Jaiyesimi
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/169
2023-07-30T12:12:22Z
jkcvhl:KCART
Impact of Body Mass Index on Survival of Metastatic Renal Cancer
Salgado Plonski, Jose Javier
Fernández-Pello, Sergio
Jiménez, Laura Rúger
Rodríguez, Iván González
Calvar, Laura Alonso
Rodríguez Villamil, Luis
body mass index
carcinoma
metastatic
renal
survival
Obesity has been established as a risk factor for renal cell carcinoma (RCC). Recently, studies have described obesity as a probable protecting factor in the metastatic stage of RCC. In this study, we assessed the relationship between body mass index (BMI) and overall survival in patients under systemic therapy.
The correlation between BMI and overall median survival was studied in 76 patients diagnosed with metastatic RCC under systemic therapy. The groups were divided into overweight and obesity (BMI > 25 kg/m2) and underweight or normal (BMI < 25 kg/m2). Statistical analysis was performed using the Cox regression model adjusted by gender.
A total of 76 patients were studied: 16 women (21%) and 60 men (79%). The median BMI was 27.96 kg/m2; 24 patients (31.6%) had low BMI and 52 (68.4%) had high BMI. Median overall survival in the group with BMI > 25 kg/m2 was 17 months (95% confidence interval [CI]: 13–34 months), while in the group with BMI ≤ 25 kg/m2, it was 14 months (95% CI: 8–20 months). When adjusted by gender, the group with BMI > 25 kg/m2 presented a hazards ratio of 0.54 (95% CI: 0.30–0.96), P = 0.044 (Log Rank).
A high BMI significantly acts as a protecting factor. We observed an increased overall survival of overweight and obese patients within the context of metastatic RCC under systemic treatment. These data confirm the findings published in other studies that suggest the role of lipid metabolism in this type of tumors.
Codon Publications
2021-07-31
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/169
10.15586/jkcvhl.v8i2.169
Journal of Kidney Cancer and VHL; Vol. 8 No. 2 (2021): Journal of Kidney Cancer and VHL; 49-54
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/169/331
https://jkcvhl.com/index.php/jkcvhl/article/view/169/333
https://jkcvhl.com/index.php/jkcvhl/article/view/169/332
Copyright (c) 2021 Jose Javier Salgado, Sergio Fernandez-Pello, Laura Ruger, Ivan Gonzalez, Laura Alonso, Luis Rodriguez-Villamil
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/170
2023-07-30T12:12:22Z
jkcvhl:KCART
Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma
W. Choi, Won Seok
Boland, Julia
Lin, Jianqing
clear cell renal cell carcinoma
HIF-2α inhibitors
hypoxia-inducible factor
pseudohypoxia
von Hippel–Lindau)
Hypoxia-inducible factor (HIF), an important mediator of hypoxia response, is implicated in tumorigenesis in the setting of pseudohypoxia, such as in the inactivation of von Hippel–Lindau tumor suppressor protein (pVHL), leading to development and progression of clear cell renal cell carcinoma (ccRCC). Targeting downstream molecules in HIF pathway, such as vascular endothelial growth factor (VEGF), has led to improvement in clinical outcome for patients with advanced ccRCC, but such therapy thus far has been limited by eventual resistance and treatment failure. Following the discovery of HIF-2α playing a key role in ccRCC carcinogenesis, inhibitors targeting HIF-2α have been developed and have demonstrated encouraging efficacy and safety profile in clinical trials. This review discusses HIF-2α as a promising therapeutic target for ccRCC.
Codon Publications
2021-04-07
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/170
10.15586/jkcvhl.v8i2.170
Journal of Kidney Cancer and VHL; Vol. 8 No. 2 (2021): Journal of Kidney Cancer and VHL; 1-7
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/170/313
https://jkcvhl.com/index.php/jkcvhl/article/view/170/315
https://jkcvhl.com/index.php/jkcvhl/article/view/170/314
Copyright (c) 2021 WonSeok W. Choi, Julia Boland, Jianqing Lin
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/171
2023-07-30T12:12:45Z
jkcvhl:PHE
Germline Pathogenic Variants Identified by Targeted Next-Generation Sequencing of Susceptibility Genes in Pheochromocytoma and Paraganglioma
Yalcintepe, Sinem
Gurkan, Hakan
Korkmaz, Fatma Nur
Demir, Selma
Atli, Engin
Eker, Damla
Sezginer Guler, Hazal
Zhuri, Drenusha
Atli, Emine Ikbal
Salt, Semra Ayturk
Sahin, Mustafa
Guldiken, Sibel
paraganglioma
pheochromocytoma
targeted sequencing
susceptibility genes
The aim of this study was to evaluate germline variant frequencies of pheochromocytoma and paraganglioma targeted susceptibility genes with next-generation sequencing method. Germline DNA from 75 cases were evaluated with targeted next-generation sequencing on an Illumina NextSeq550 instrument. KIF1B, RET, SDHB, SDHD, TMEM127, and VHL genes were included in the study, and Sanger sequencing was used for verifying the variants. The pathogenic/likely pathogenic variants were in the VHL, RET, SDHB, and SDHD genes, and the diagnosis rate was 24% in this study. Three different novel pathogenic variants were determined in five cases. This is the first study from Turkey, evaluating germline susceptibility genes of pheochromocytoma and paraganglioma with a detection rate of 24% and three novel variants. All patients with pheochromocytoma and paraganglioma need clinical genetic testing with expanded targeted gene panels for higher diagnosis rates.
Codon Publications
2021-03-13
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/171
10.15586/jkcvhl.v8i1.171
Journal of Kidney Cancer and VHL; Vol. 8 No. 1 (2021): Journal of Kidney Cancer and VHL; 19-24
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/171/307
https://jkcvhl.com/index.php/jkcvhl/article/view/171/309
https://jkcvhl.com/index.php/jkcvhl/article/view/171/308
Copyright (c) 2021 Sinem Yalcintepe, Hakan Gurkan, Fatma Nur Korkmaz, Selma Demir, Engin Atli, Damla Eker, Hazal Sezginer Guler, Drenushe Zhuri, Emine Ikbal Atli, Semra Ayturk Salt, Mustafa Sahin, Sibel Guldiken
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/173
2022-03-30T07:12:10Z
jkcvhl:KCCR
Exceptional Renal Metastasis from Adenoid Cystic Carcinoma of the Nasal Cavity and Literature Review
Feki, Jihene
Lajnef, Maissa
Mallouli, Manel
Ben mahfoudh, Kheireddine
Boudawara, Tahia
Khanfir, Afef
adenoid cystic
carcinoma
nasal cavity
kidney
renal metastases
Adenoid cystic carcinoma (ACC) is a rare malignant cancer that arises from secretory glands. Slow growth, perineural invasion, and late recurrences are the main characteristics of ACC. Only few cases of kidney metastases from ACC have been reported in the literature. We report here the case of a 66-year-old female patient who presented with bilateral renal metastases from ACC of the nasal cavity, detected 14 years after treatment of primary tumor and 6 years after metastasectomy of lung metastases. Histological examination confirmed diagnosis and the patient was treated with systemic chemotherapy. Radiological evaluation showed stability of the disease. However, a progression with occurrence of metastases in other sites (lung and bones) has been observed after 7 months. She is still receiving second-line chemotherapy. To the best of our knowledge, this is the second case of kidney metastases from ACC of the nasal cavity.
Codon Publications
2021-09-23
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/173
10.15586/jkcvhl.v8i3.173
Journal of Kidney Cancer and VHL; Vol. 8 No. 3 (2021): Journal of Kidney Cancer and VHL; 19-21
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/173/346
https://jkcvhl.com/index.php/jkcvhl/article/view/173/348
https://jkcvhl.com/index.php/jkcvhl/article/view/173/347
Copyright (c) 2021 Jihene Feki, Maissa Lajnef, Manel Mellouli, Kheireddine Ben mahfoudh, Tahia Boudawara, Afef Khanfir
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/175
2023-07-30T12:12:22Z
jkcvhl:KCCR
Papillary Renal Cell Carcinoma in Lynch/Muir-Torre Syndrome with Germline Pathogenic Variant in MSH6 and Molecular Analysis: Report of a Case and Review of the Literature
Yang, Yu
Dhar, Shweta
Taylor, Jennifer
Krishnan, Bhuvaneswari
colon adenocarcinoma
Lynch syndrome
MSH6 mutation
Muir-Torre syndrome
Papillary renal cell carcinoma.
Lynch syndrome (LS) is an autosomal dominant inherited disorder due to pathogenic variations in the mismatch repair genes, which predisposes to malignancies, most commonly colon and endometrial carcinoma. Muir-Torre syndrome is a subset of LS with cutaneous sebaceous adenoma and keratoacanthoma in addition to the malignancies. Renal cell carcinoma (RCC) in patients with LS is extremely rare. Only 26 cases have been reported and among them, only two cases of papillary RCC. We report a case of synchronous papillary RCC and colonic adenocarcinoma in an 85-year-old male with Lynch/Muir-Torre syndrome. The LS was diagnosed when he presented with multiple sebaceous adenomas and genetic testing showed a pathogenic variant in MSH6 mismatch repair gene. A colonoscopy at that time showed multiple tubular adenomas with high-grade dysplasia. He was lost to follow-up and presented with gastrointestinal bleeding after 20 years. A right colonic mass, and a solid mass in the lower pole of the right kidney, was detected by imaging. Right Colectomy showed a T3N0 mucin-producing adenocarcinoma. Right nephrectomy showed a T3a papillary RCC which was microsatellite stable with MSH6, and KRAS mutation. The 36-month follow-up exams showed additional sebaceous neoplasms, and an absence of metastatic carcinoma. Analysis of the reported cases of RCC in LS show clear cell RCC as the most common type. These tumors showed MLH1 mutation most commonly, unlike the urothelial malignancies in LS which involve MSH2. Among the 4 cases of RCC with MSH6 mutation, three were in females, indicating some gender differences.
Codon Publications
2021-04-21
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/175
10.15586/jkcvhl.v8i2.175
Journal of Kidney Cancer and VHL; Vol. 8 No. 2 (2021): Journal of Kidney Cancer and VHL; 8-19
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/175/316
https://jkcvhl.com/index.php/jkcvhl/article/view/175/318
https://jkcvhl.com/index.php/jkcvhl/article/view/175/317
Copyright (c) 2021 Yu Yang, Shweta Dhar, Jennifer Taylor, Bhuvaneswari Krishnan
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/177
2023-07-30T12:11:22Z
jkcvhl:NR
New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature
Álvarez Restrepo, Juan Camilo
Castañeda Millan, David Andres
Riveros Sabogal, Carlos Andres
Puentes Bernal, Andres Felipe
Donoso Donoso, Wilfredo
angiomyolipoma
diagnosis
kidney neoplasms
review
therapeutics
Treatment of renal angiomyolipoma (AML) seeks to reduce related complications and preserve kidney function. The purpose of this article was to perform an updated literature review on the diagnosis, therapeutic options, and criteria for invasive intervention in patients with renal AML. Computerized tomography is the standard diagnostic method for renal AML, while definitive diagnosis is made by histopathology. The management of choice in most cases is active surveillance (AS), with a clinical and imaging follow-up protocol. In high-risk cases, therapeutic management should be considered, with alternatives such as selective arterial embolization (SAE), nephron-sparing surgery (NSS), and mTOR inhibitors in selected patients. Renal AML in women of childbearing age, those with growth >0.25 cm/year, intralesional aneurysms >5 mm, and clinically significant symptoms may qualify for active treatment. Despite the limitations derived from the available evidence, it is possible to consider SAE, NSS, and the use of mTOR inhibitors as management alternatives for selected patients.
Codon Publications
2022-01-21
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/177
10.15586/jkcvhl.v9i1.177
Journal of Kidney Cancer and VHL; Vol. 9 No. 1 (2022): Journal of Kidney Cancer and VHL; 33-41
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/177/382
https://jkcvhl.com/index.php/jkcvhl/article/view/177/384
https://jkcvhl.com/index.php/jkcvhl/article/view/177/383
Copyright (c) 2021 Juan Camilo Álvarez Restrepo, David Andres Castañeda Millan, Carlos Andres Riveros Sabogal, Andres Felipe Puentes Bernal, Wilfredo Donoso Donoso
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/178
2023-07-30T12:12:22Z
jkcvhl:KCCR
Renal Epithelioid Angiomyolipoma in Children
Mahajan, Dhruv
Jain, Vishesh
Agarwala, Sandeep
Jana, Manisha
Ramteke, Prashant P
angiomyolipoma
kidney tumor
pediatric cancer
renal epithelioid angiomyolipoma
tuberous sclerosis
Renal angiomyolipoma is a rare cause of renal tumor in children. Most are associated with tuberous sclerosis, and the classic type is observed more commonly. Epithelioid angiomyolipoma is even rarer with only limited case reports and series published in literature, most of which are of adult patients. We describe a 12-year-old boy, a diagnosed patient of tuberous sclerosis, who presented with pain in the left flank. On evaluation, it was found to have a left renal mass with the clinical picture suggestive of renal cell carcinoma. Partial nephrectomy was performed and histopathology revealed epithelioid angiomyolipoma. The child was asymptomatic at follow-up after 3 months. Only a few such cases in children are found in literature, which are discussed alongside. Differential diagnosis of this rare tumor must be kept in mind in a renal tumor as surgery is generally curative in this possibly malignant tumor. Metastasis confers a poor prognosis. Chemotherapy is generally not effective, although various regimens have been tried. Tumor recurrence must be kept in mind and a follow-up after apparent complete remission is of paramount importance.
Codon Publications
2021-06-04
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/178
10.15586/jkcvhl.v8i2.178
Journal of Kidney Cancer and VHL; Vol. 8 No. 2 (2021): Journal of Kidney Cancer and VHL; 20-26
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/178/319
https://jkcvhl.com/index.php/jkcvhl/article/view/178/321
https://jkcvhl.com/index.php/jkcvhl/article/view/178/320
Copyright (c) 2021 Dhruv Mahajan, Vishesh Jain, Sandeep Agarwala, Manisha Jana, Prashant P Ramteke
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/179
2023-07-30T12:12:22Z
jkcvhl:KCART
Partial Nephrectomy, a Comparison between Different Modalities: A Tertiary Care Center Experience
Al Asker, Ahmed
Addar, Abdulmalik
Alghamdi, Mohammed
Alawad, Saud
Alharbi, Mohammed
Bin Hamri, Saeed
Albqami, Nasser
Alkhayal, Abdullah
Alrabeeah, Khaled
partial nephrectomy
robotic surgrey
nephron sparing
ischemia time
Kidney cancer, with 4% of all malignancies, is one of the most common malignancies occurring among in adults. In Saudi Arabia, kidney cancer comprises 2.3% of all cancers, and its incidence has increased by 33%. Partial nephrectomy (PN) is considered as the gold standard for T1 renal masses.
In this retrospective study, we did a chart review for all patients who underwent PNs between April 2013 and February 2019. Data comprised presentation, tumor size, type of procedure (open vs. laparoscopic vs. robotic), and intra- and post-operative complications. Chi-square, ANOVA, and cross-tabulation were done using SPSS software. P > 0.05 was considered significant. Approval was obtained from the institutional review board of King Abdullah International Medical Research Center.
In all, 69 patients were identified: 26 (37.7%) males and 43 (62.3%) females, with mean age = 54.53 ± 13.21 years; mean body mass index = 32.36 ± 7.03, and mean tumor size = 3.7 ± 1.72 cm. In terms of presentation, most patients (50, 72.4%) presented incidentally as opposed to symptomatic presentation. Of these patients, 18 (26.1%) underwent open partial nephrectomy (OPN), 29 (42%) laparoscopic partial nephrectomy (LPN), and 22 (31.9%) robotic partial nephrectomy (RPN). On comparing minimally invasive surgery (MIS) PN with OPN, we found that OPN had more blood loss and a longer hospital stay but a shorter operating room (OR) time.
Results of PN irrespective of the procedure type, whether it was OPN, LPN, or RPN, were similar if performed by experienced surgeons. However, open procedures involved a higher blood loss, more operative time, and longer hospital stay when compared with minimally invasive techniques.
Codon Publications
2021-06-17
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/179
10.15586/jkcvhl.v8i2.179
Journal of Kidney Cancer and VHL; Vol. 8 No. 2 (2021): Journal of Kidney Cancer and VHL; 34-39
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/179/325
https://jkcvhl.com/index.php/jkcvhl/article/view/179/327
https://jkcvhl.com/index.php/jkcvhl/article/view/179/326
Copyright (c) 2021 Ahmed Al Asker, Abdulmalik Addar, Mohammed Alghamdi, Saud Alawad, Mohammed Alharbi, Saeed Bin Hamri, Nasser Albqami, Abdullah Alkhayal, Khaled Alrabeeah
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/181
2022-03-30T07:11:58Z
jkcvhl:KCCR
Different Treatments of Symptomatic Angiomyolipomas of the Kidney: Two Case Reports
Pacella, Giuseppina
Faiella, Eliodoro
Altomare, Carlo
Andresciani, Flavio
Castiello, Gennaro
Bernetti, Caterina
Sarli, Marina
Beomonte Zobel, Bruno
Grasso, Rosario Francesco
angiomyolipomas
cryoablation
transarterial embolization
Development of more sensitive imaging techniques has caused an increase in the number of diagnosed small renal tumors. Approximately 2–3% of these lesions are proved to be angiomyolipomas (AML), a rare benign tumor of the kidney sometimes causing pain and hematuria. The most required approach is observation, but in the case of recurrent symptoms or larger tumors, which may cause bleeding, a more active treatment is required. We present two cases of symptomatic AML tumors of different sizes in the kidney: one treated with transarterial embolization (TAE), and the other with percutaneous cryoablation (CRA). The lesions were diagnosed on the basis of contrast-enhanced computed tomography (CT) scan and magnetic resonance imaging (MRI). Both treatments proved to be effective and safe for treating renal AMLs. A follow-up carried out, based on contrast-enhanced CT scan, confirmed complete treatment of AML and decreased lesion size. There are myriad minimally invasive approaches for the treatment of renal AMLs, and the preservation of renal function remains a priority. The most popular treatment option is the selective renal artery embolization. Owing to its limited invasiveness, CRA could be an attractive option for the preventive treatment of AML.
Codon Publications
2021-10-19
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/181
10.15586/jkcvhl.v8i4.181
Journal of Kidney Cancer and VHL; Vol. 8 No. 4 (2021): Journal of Kidney Cancer and VHL; 32-37
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/181/361
https://jkcvhl.com/index.php/jkcvhl/article/view/181/363
https://jkcvhl.com/index.php/jkcvhl/article/view/181/362
Copyright (c) 2021 Giuseppina Pacella, Eliodoro Faiella, Carlo Altomare, Flavio Andresciani, Gennaro Castiello, Caterina Bernetti, Bruno Beomonte Zobel, Rosario Francesco Grasso
https://creativecommons.org/licenses/by-nc-nd/4.0
oai:ojs.pkp.sfu.ca:article/182
2022-03-30T07:11:58Z
jkcvhl:WT
Genetic Polymorphisms of the TGFB1 Signal Peptide and Promoter Region: Role in Wilms Tumor Susceptibility?
Ishibashi, Cintya Mayumi
Coral de Oliveira, Carlos Eduardo
Guembarovski, Roberta Losi
Banin Hirata, Bruna Karina
Freire Vitiello, Glauco Akelinghton
Guembarovski, Alda Losi
Amarante, Marla Karine
de Oliveira, Karen Brajão
Kishima, Marina Okuyama
Ariza, Carolina Batista
Ehara Watanabe, Maria Angelica
genetic polymorphism
nephroblastoma
prognosis
susceptibility
TGFB1
Wilms tumor
The aim of the present study was to investigate the rs1800468 (G-800A), rs1800469 (C-509T), rs1800470 (C29T), and rs1800471 (G74C) TGFB1 genetic polymorphisms and their haplotype structures in patients with Wilms Tumor (WT) and neoplasia-free controls. The genomic DNA was extracted from 35 WT patients and 160 neoplasia-free children, and the TGFB1 polymorphisms were genotyped by polymerase chain reaction, followed by restriction fragment length polymorphism. The haplotype structures were inferred, and permutation and logistic regression tests were performed to check for differences in haplotype distribution between the control and WT individuals. Positive associations were found in the recessive model for rs1800469 T allele (OR: 8.417; 95% CI: 3.177 to 22.297; P < 0.001) and for the rs1800470 C allele (OR: 3.000; 95% CI: 1.296 to 6.944; P = 0.01). Haplotype analysis revealed a significant negative association between GCTG and WT (OR: 0.236, 95% CI: 0.105 to 0.534; P = 0.0002); by contrast, the GTTG haplotype was associated with increased risk for WT (OR: 12.0; 95% CI: 4.202 to 34.270; P < 0.001). Furthermore, rs1800469 was negatively correlated with tumor size and a trend toward a positive correlation for capsular invasion was observed in the dominant model (Tau-b: −0.43, P = 0.02 and tau-b: 0.5, P = 0.06, respectively). This is the first study with rs1800468, rs1800469, rs1800470, and rs1800471 TGFB1 polymorphisms in WT, and our results suggest that the TGFB1 promoter and signal peptide region polymorphisms may be associated with WT susceptibility and clinical presentation.
Codon Publications
2021-10-16
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
application/pdf
text/html
text/xml
https://jkcvhl.com/index.php/jkcvhl/article/view/182
10.15586/jkcvhl.v8i4.182
Journal of Kidney Cancer and VHL; Vol. 8 No. 4 (2021): Journal of Kidney Cancer and VHL; 22-31
2203-5826
eng
https://jkcvhl.com/index.php/jkcvhl/article/view/182/358
https://jkcvhl.com/index.php/jkcvhl/article/view/182/360
https://jkcvhl.com/index.php/jkcvhl/article/view/182/359
Copyright (c) 2021 Cintya Mayumi Ishibashi, Carlos Eduardo Coral de Oliveira, Roberta Losi Guembarovski, Bruna Karina Banin-Hirata, Glauco Akelinghton Freire Vitiello, Alda Losi Guembarovski, Marla Amarante, Karen Brajão de Oliveira, Marina Okuyama Kishima, Carolina Batista Ariza, Maria Angelica Ehara Watanabe
https://creativecommons.org/licenses/by-nc-nd/4.0
f5d23e05ccde5e0fefe594b51ffa02eb